Minimal Residual Disease is A Vital Marker for Patients with Multiple Myeloma, Says Expert
July 31, 2020 – Dr. Parameswaran Hari
EDUCATED PATIENT CLL Webinar: Looking at the CLL Landscape
July 30, 2020 – CURE Staff
No 'One Great Answer' When it Comes to What Rights Those Affected By Cancer Have When Returning to Work Amid COVID-19
July 29, 2020 – Ryan McDonald and Monica Bryant
Gut Microbiome May Play an Important Role in Immunotherapy in the Future, But More Research is Needed
July 28, 2020 – Jessica Skarzynski
CURE Community Vlogs: How One Woman Found Her Way Out of Depression Following Metastatic Breast Cancer
July 26, 2020 – Stephanie Walker
CURE Community Vlogs: Laughter As Therapy
July 25, 2020 – Khevin Barnes
Advice for Avoiding the Isolation That Comes with Metastatic Breast Cancer
July 24, 2020 – Stephanie Walker
Success and Momentum Involving Biomarkers in Lung Cancer Has Led to More Treatment Options for Patients
July 23, 2020 – Dr. Jorge Gomez
CURE Community Vlogs: Staying Active At Home Through Virtual Yoga
July 18, 2020 – Tamera Anderson-Hanna
Immunotherapy Could Signal a 'Change in the Treatment Paradigm' For Patients with HCC
July 16, 2020 – Jessica Skarzynski
Expert Highlights 'Exciting' Future Developments in Lung Cancer Treatment
July 16, 2020 – Ryan McDonald and Dr. Timothy Burns
Chemotherapy Type and Sequence Can Impact Hair Retention in Breast Cancer
July 15, 2020 – Dr. Julie Rani Nangia
Scalp Cooling: How Does It Work and How Safe Is It?
July 14, 2020 – Dr. Julie Rani Nangia
CURE Community Vlog: Cancer Diagnoses Can Be a Distant Memory
July 13, 2020 – Kristie L. Kahl
Out of Several Recent Drug Approvals in NSCLC, Tabrecta Most 'Practice Changing' of All, According to Expert
July 13, 2020 – Ryan McDonald and Timothy Burns
CURE Community Vlog: Having Great Purpose in Pain After Cancer
July 12, 2020 – Ian Macleod
CURE Community Vlog: One Patient's Journey With Merkel Cell Carcinoma
July 11, 2020 – Kristie L. Kahl
Expert Addresses Fear and Uncertainty Patients with Cancer Feel from COVID-19 Disruptions
July 10, 2020 – Dr. Pat Basu
'Mixed Bag': Only a Fraction of Recent Drug Approvals in NSCLC Space 'Considered Practice Changing'
July 10, 2020 – Ryan McDonald and Dr. Timothy Burns
Tecentriq Approval in NSCLC 'Stops the Brakes' on PD-L1 Expression
July 08, 2020 – Dr. Jorge Gomez
Turning Clinical Results Into Change for Patients with Prostate Cancer
July 08, 2020 – Dr. Michael Morris
How COVID-19 Has Created a 'Shadow Curve' in the Treatment of Cancer and Other Diseases
July 08, 2020 – Dr. Pat Basu
The Importance of More Thoughtful Treatment Strategies in High-Risk CLL
July 02, 2020 – Dr. Mazyar Shadman
CURE Community Vlogs: Recommendations On What To Do After Receiving a Cancer Diagnosis
July 01, 2020 – Lidia Vitale
Expert Breaks Down the Three Treatment Modalities Currently Being Investigated in CLL
June 30, 2020 – Dr. Mazyar Shadman
Expert Advises Patients with CLL on Three Things They Should Be Aware of To Maximize the Benefit of Upfront Treatment
June 29, 2020 – Ryan McDonald and Dr. Mazyar Shadman
What Factors Play a Role in Determining Optimal First Line Treatment for Patients With CLL
June 26, 2020 – Ryan McDonald and Mazyar Shadman
Approval of Alunbrig Offers Another Option for ALK-Positive NSCLC, But More Research Is Needed
June 23, 2020 – Jessica Skarzynski
CURE Community Vlogs: Making the Little Moments Count Through Cancer
June 21, 2020 – Ashley Stringer
CURE Community Vlogs: Turning Lemons into Lemonade After a Cancer Diagnosis
June 20, 2020 – Danielle
CURE EDUCATED PATIENT CLL Webinar
June 19, 2020 – CURE Staff
Keytruda Plus Chemotherapy Improves Survival Outcome in Metastatic Triple-Negative Breast Cancer
June 19, 2020 – Dr. Javier Cortes
EDUCATED PATIENT Lung Cancer Webinar: Western Region
June 19, 2020 – CURE Staff
An Expert Offers Advice on How to Incorporate Exercise Into Your Daily Routine
June 19, 2020 – Laurie Hatch
Investigational Drug Combination Could Address Unmet Need in TP53-Positive MDS
June 18, 2020 – Dr. Guillermo Garcia-Manero
Expert Explains Potential Long-term Impact of Yescarta CAR-T Cell Therapy For Patients with Lymphoma
June 17, 2020 – Caron A. Jacobson, MD
Ethan Zohn: Cancer Treatment is "A Marathon, Not a Sprint"
June 16, 2020 – Ethan Zohn
An Oncology Dietitian Offers Some Healthy Snack Options to Combat Stress Eating
June 16, 2020 – Rachel Wong, RD, CSO, LD
Expert Discusses Side Effects of Keytruda That Patients with Hodgkin Lymphoma Should Know About
June 15, 2020 – John Kuruvilla, MD
Facing the Challenges of Young Adult Cancer By Finding a Community
June 14, 2020 – Ethan Zohn
Expert Discusses the Importance of 'Exercise as Medicine' for Patients with Cancer and Survivors
June 13, 2020 – Laurie Hatch
Acceptance is Vital to Getting Through Cancer and COVID-19, Says Survivor Ethan Zohn
June 11, 2020 – Ethan Zohn
Autologous Stem Cell Transplant Should Remain Standard of Care for Certain DLBCL Patients, Expert Says
June 09, 2020 – Nirav Niranjan Shah, MD
Survivor Ethan Zohn Takes On the Log Challenge for Leukemia and Lymphoma Awareness
June 09, 2020 – Jessica Skarzynski
Shelf-Stable Pantry Staples Patients and Survivors Can Rely On During a Pandemic
June 07, 2020 – Rachel J. Wong, RD, CSO, LD.
EDUCATED PATIENT Lung Cancer Webinar: Eastern Region
June 01, 2020 – CURE Staff
Triplet Therapy Reduces Risk of Death in Patients With HER-2 Positive Breast Cancer Who Developed Brain Metastases
May 31, 2020 – Dr. Nancy U. Lin
Triplet Therapy for Certain Patients with Metastatic Colorectal Cancer Shows Promise, But More Research is Needed
May 30, 2020 – Conor Killmurray
MK-6482 Shows Promise in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
May 30, 2020 – Dr. Eric Jonasch
Revlimid and Rituxan Combo 'Another Potential Option' For Patients With Mantle Cell Lymphoma
May 30, 2020 – Dr. Ian Flinn
In the 'Midst of a Real Shakeup': Perspective on Next Few Years of Mantle Cell Lymphoma Treatments
May 27, 2020 – Dr. Ian Flinn
How Patients and Survivors Can Use Meal Planning to Make the Most of Their Grocery Store Trips
May 26, 2020 – Rachel J. Wong, RD, CSO, LD.
'Exciting Advancements' Coming in The Treatment of Lymphomas
May 26, 2020 – Dr. Ian Flinn
'A Lot of Action' in The Development of Targeted Therapies for Mantle Cell Lymphoma
May 22, 2020 – Dr. Ian Flinn
Currently Viewing
EDUCATED PATIENT Lung Cancer Webinar: Midwest Region
May 22, 2020 – CURE Staff
How Cancer Caregivers Can Stay Connected With Their Loved Ones While Social Distancing
May 20, 2020 – Martha Raymond
How Patients With Cancer Should Approach Questions Surrounding the Final Outcome of COVID-19, Their Diagnosis
May 20, 2020 – Dr. Scott Irwin
'More Important Now' For Patients with Cancer to Focus on Mental Health During COVID-19
May 19, 2020 – Dr. Scott Irwin
Don't Ignore the Warning Signs of Cancer, Even During a Pandemic
May 19, 2020 – Diane Zipursky Quale
Patients with Cancer Can Teach Others About Resilience in the Face of the COVID-19 Pandemic
May 18, 2020 – Martha Raymond
What Patients with Bladder Cancer Can Do When COVID-19 Impacts Their Care
May 16, 2020 – Diane Zipursky Quale
How COVID-19 Has Impacted one Non-Profit's Fundraising Efforts for Breast Reconstruction Surgery After Cancer
May 15, 2020 – Morgan Hare
Facts Matter for Patients with Cancer During the COVID-19 Pandemic, Says One Advocate
May 15, 2020 – Martha Raymond
How One Organization is Honoring Bladder Cancer Awareness Month During the COVID-19 Pandemic
May 14, 2020 – Diane Zipursky Quale
One Nonprofit is Sticking to its Mission for Patients With Breast Cancer During the COVID-19 Pandemic
May 12, 2020 – Morgan Hare
How COVID-19 Has Impacted Anxiety, Mental Health in Patients with Cancer
May 12, 2020 – Dr. Scott Irwin
Telemedicine: How to Find the Right Virtual Health Care
May 10, 2020 – Jessica Skarzynski
CURE Community Vlog: Breathing Techniques to Use During Quarantine
May 09, 2020 – Ian Macleod
How Patients with Chronic Lymphocytic Leukemia Are Equipped to Handle the COVID-19 Pandemic
May 04, 2020 – Brian Koffman
Communication Remains an Important Tool for Cancer Caregivers
May 01, 2020 – Sarah Miretti Cassidy
Hear From the Experts: COVID-19 and Cancer Care for Patients
May 01, 2020 – CURE Staff
How Social Distancing Helped Create a Sense of Community Among Some Patients with CLL
April 30, 2020 – Brian Koffman
Rescheduling Breast Reconstruction Post-Pandemic Will Present 'Interesting Logistical Puzzle' For Some
April 30, 2020 – Ryan McDonald
How COVID-19 Has Impacted Clinical Trials for Chronic Lymphocytic Leukemia
April 29, 2020 – Brian Koffman
The Pros and Cons of Delaying Breast Reconstruction Surgery During the COVID-19 Pandemic
April 29, 2020 – Ryan McDonald
CURE Community Vlog: Staying Healthy During the COVID-19 Pandemic
April 29, 2020 – Salima Witt
The 'Difficult Conversations' About Delaying Breast Reconstruction Surgery During the COVID-19 Pandemic
April 28, 2020 – Ryan McDonald
CURE Community Vlog: Winning Despite 'Being Dealt a Bad Hand' After Cancer
April 28, 2020 – Sally Kalksma
How Patients with Cancer and Survivors Can Maintain Good Sleep Hygiene Through the COVID-19 Pandemic
April 26, 2020 – Dr. Kathryn Ruble
Weighing the Risks and Benefits of Colorectal Cancer Treatment During the COVID-19 Pandemic
April 25, 2020 – Jessica Skarzynski
CURE Community Vlog: Making the Little Moments Count During Cancer
April 24, 2020 – Ashley Stringer
Moving Away from Chemotherapy to Treat HR-Positive/HER2-Negative Metastatic Breast Cancer
April 23, 2020 – Melissa K. Accordino, MD, MS
How One Organization is Helping Patients with Blood Cancers Through the COVID-19 Pandemic
April 21, 2020 – Jessica Skarzynski
CURE Community Vlog: Taking Control Over a Cancer Diagnosis
April 21, 2020 – Salima Witt
Rob Paulsen on Facing Cancer and the Pandemic with a Smile
April 18, 2020 – Jessica Skarzynski
CURE Community Vlog: Finding Something Positive When Faced With Adversity
April 16, 2020 – Sally Kalksma
A Patient with Ovarian Cancer Weathers the COVID-19 Storm at Her Local Health Center
April 16, 2020 – Ryan McDonald
Attending Education Events is Beneficial to Patients and Clinicians
April 16, 2020 – Dr. Irum Khan
Offering a Lifeline to Adolescents and Young Adults With Cancer During the COVID-19 Pandemic
April 15, 2020 – Jessica Skarzynski
Cancer Survivors Should Discuss COVID-19 Risks with Their Health Care Providers
March 25, 2020 – Dr. Sara Hurvitz
'Maximum Amount of Caution' Necessary for Immunosuppressed Patients Amid COVID-19 Pandemic
March 23, 2020 – Patrick I. Borgen, MD
CURE New Issue Alert: 2020 Hematology Special Edition-1
March 12, 2020 – Jessica Skarzynski
New Issue Alert: Heal Winter 2020
March 02, 2020 – Katie Kosko and Jessica Skarzynski
CURE's Top Stories: February 2020
March 02, 2020 – Jessica Skarzynski
Combination Therapies Open New Doors in Renal Cell Carcinoma Studies
February 25, 2020 – Bradley McGregor, M.D.
New Issue Alert: CURE Winter 2020
February 25, 2020 – Katie Kosko and Jessica Skarzynski
Aiming for Long Term Success in Kidney Cancer Treatment
February 24, 2020 – Jessica Skarzynski
Immune Checkpoint Inhibition Could Be the Future of Renal Cell Carcinoma Treatment
February 23, 2020 – Dr. Thomas Powles
Novel HER-2 Targeted Agents Show Promise in Treating CNS Metastases
February 20, 2020 – Nancy Lin, M.D.
Padcev, Keytruda Combination Proves Impactful for Patients with Metastatic Urothelial Cancer
February 19, 2020 – Jonathan Rosenberg, M.D.
Disparities Exist in Young Patients with Colorectal and Gastric Cancers
February 03, 2020 – Amir Khan, MD
CURE's Top Stories: January 2020
February 01, 2020 – Jessica Skarzynski
Updates From a PARP Inhibitor Clinical Trial for Patients with Metastatic Pancreatic Cancer
January 31, 2020 – Teresa Macarulla, M.D.
Blood-Based Test Detects Gastrointestinal Cancers with High Accuracy, Study Finds
January 30, 2020 – Brian M. Wolpin, M.D., M.P.H.
Patient-Reported Outcomes Improve with Combination Treatment for Some Patients With Hepatocellular Carcinoma
January 29, 2020 – Peter Galle, M.D., Ph.D
Targeted Therapies Improve Overall Survival for Patients With Colorectal Cancer Subtype
January 28, 2020 – Scot Kopetz, M.D., Ph.D., FACP
Addressing the Symptom Burden of Patients With MPN
January 23, 2020 – Robyn Scherber, M.D., M.P.H.
MPN Hero Advocates For Patients Enrolled In Clinical Trials
January 22, 2020 – Kurt Schroeder, RN
Advocating for Education of Myeloproliferative Neoplasms
January 21, 2020 – Ann McMullin
How Translational Research Brings Research Outcomes To The Bedside
January 20, 2020 – Dr. David C. Fajenbaum
In Cancer Treatment, Immunotherapy is a Viable Option Despite Toxicities
January 17, 2020 – Dr. Mario Sznol
MPN Hero Discusses Providing Immediate Cancer Care By Circumventing The Emergency Room
January 16, 2020 – Laura Michaelis, MD
Eleven-Year-Old MPN Hero Remains Positive in the Face of Uncertainty
January 14, 2020 – Cannon McMullin
MPN Hero Advocates for Her Daughter Until The Right Diagnosis Is Made
January 13, 2020 – Natalie Catalano
MPN Hero Bridges the Care Gap to Address Mental Health Issues in Patients with MPNs
January 10, 2020 – Madeleine Henriquez, PA-C
BTK Inhibitor Use Proves Beneficial in Mantle Cell Lymphoma Treatment
January 07, 2020 – Dr. Simon Rule
MPN Hero Advocates For Individualized Patient Care
January 06, 2020 – Dr. Irum Khan
Limiting Treatment Duration Improves Cost Effectiveness in CLL
January 05, 2020 – Dr. Matthew Davids
Patients with Breast Cancer Who Face Treatment Disparities Grow Their Role at Major Medical Conference
December 26, 2019 – Maimah Karmo
HER2+ mBC: DESTINY-Breast04 Trial
December 24, 2019 – Sponsored Content
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
December 22, 2019 – Sponsored Content
Management of HER2 Expression in Breast Cancer
December 20, 2019 – Sponsored Content
Ibrance Shows Promise in Patients with Brain Metastases Who Harbor a CDK Pathway Alteration
December 18, 2019 – Dr. Pamela Brastianos
Education and Teamwork Are Key in the Treatment of MPNs
December 16, 2019 – Tammy Matuska, B.S.N., RN
The Future of Novel Immunotherapy Combinations in Melanoma
December 09, 2019 – Dr. Georgina Long
The Importance of Clinical Trials in Multiple Myeloma
December 06, 2019 – Dr. Sham Mailankody
Stomping Out the Smoking Stigma for Patients with Lung Cancer
December 05, 2019 – Sarah Christ
Looking Out for Side Effects in Immunotherapy Combination Treatment
December 04, 2019 – Nagashree Seetharamu, MD, MBBS
CAR T-Cell Therapy for Patients with Lymphoma
December 04, 2019 – Dr Miguel-Angel Perales
Common Mutations Could Lead to Targeted Treatment for Patients with Brain Metastases
December 03, 2019 – Dr. Priscilla Brastianos
Utilizing Psychosocial Data to Help Patients with Lung Cancer
December 02, 2019 – Kelly Clark, MA
Being Open About Mental Health Care During Cancer Treatment
November 13, 2019 – Nancy Cohen
New Targeted and Immunotherapy Options in Lung Cancer
November 11, 2019 – Dr. Hossein Borghaei
The Search for Biomarkers in Renal Cell Carcinoma
November 08, 2019 – Dr. Brian I. Rini
Patient Concerns and Treatment Decisions Are Impacted by Disease Stage
October 14, 2019 – Dr. Sara Hurvitz
Efficacy and Safety Are Key Factors When Selecting Breast Cancer Treatment
October 09, 2019 – Dr. Sara Hurvitz
Jevtana's Toxicity Profile Makes It a Good Option in Metastatic Prostate Cancer
October 08, 2019 – Dr. Arash Rezazadeh Kalebasty
Third-Line Jevtana Improves Progression-Free Survival in Prostate Cancer Subtype
October 07, 2019 – Dr. Daniel Petrylak
Novel Agents Are Changing the Prostate Cancer Treatment Landscape
October 04, 2019 – Dr. Daniel George
Patients Play an Important Role in Cancer Treatment
October 02, 2019 – Dr. Sara Hurvitz
Older Patients With Mantle Cell Lymphoma Benefit Most From Individualized Treatment
September 13, 2019 – Dr. Peter Martin
MMRF Expert Offers Update on Multiple Myeloma Trials
September 04, 2019 – Chris Williams
Investing in Every Patient: Katie Couric Shares Cancer Support and Resources
August 16, 2019 – Katie Couric
Katie Couric: 'If I Could Say Something to My Younger Self'
August 09, 2019 – Katie Couric
Kerry Fraser Talks Cancer Treatment
August 06, 2019 – Kerry Fraser
A Three-Time Cancer Survivor Finds a 'Ray of Light' and Opens Up About Her First Diagnosis
August 05, 2019 – Valerie David
Katie Couric: Cancer Caregivers May Feel Alone, But You're Not
August 02, 2019 – Katie Couric
Kerry Fraser: Finding a 'New Normal' After a Cancer Diagnosis
July 30, 2019 – Kerry Fraser
What Being a Survivor Means to 'The Pink Hulk', a Three-Time Cancer Survivor
July 29, 2019 – Valerie David
Caregiver, Survivor and Advocate: Katie Couric
July 26, 2019 – Katie Couric
Kerry Fraser: Advice for Newly Diagnosed Patients with Cancer
July 24, 2019 – Kerry Fraser
Investigating Clinical Trials, Treatments and Facing Cancer Setbacks with Katie Couric
July 19, 2019 – Katie Couric
Bitter or Better? Changing The Way You Perceive Your Diagnosis
July 12, 2019 – Rolf Benirschke
Adapting to the New Normal When a Loved One Has Cancer
July 11, 2019 – Katie Couric
Being a Caregiver: The Unsung Heroes of Cancer
July 02, 2019 – Katie Couric
Katie Couric's Advice on Helping Children Cope With a Parent's Cancer Diagnosis
June 27, 2019 – Katie Couric
Katie Couric Speaks About Grief and Moving on After Losing Loved Ones to Cancer
June 20, 2019 – Katie Couric
Komen NYC Educates Women About Breast Cancer Screening
June 06, 2019 – Linda Tantawi
More Than Friends Sends a Message of Health at Annual Tea Party
May 16, 2019 – More Than Friends
'Caring and Sharing' Baskets: A Few of Your Favorite Things During Radiation and Chemotherapy Treatment
May 08, 2019 – Joanne Edwards
More Than Friends Organization: Bringing Help and Hope to Cancer Survivors
May 06, 2019 – Elise Bourne-Busby
Keeping the Dream Alive: Supporting Female Survivors
April 29, 2019 – Barbara Bittner, RN, OCN
Running to Raise Money and Awareness for Cancer
April 26, 2019 – Angela Hammack, B.S.N., RN, OCN
Finding Emotional Support in a Health Care Team
April 24, 2019 – Caitlin Cohen, M.S.N., RN, CPNP-AC, CPHON
Giuliana Rancic: Finding the Light at the End of the Tunnel
April 22, 2019
Ovarian Cancer Treatments 'Coming Down the Pike' Create Resurgence for Patients
April 12, 2019 – Shannon Westin, M.D., M.P.H.
'Connection is Key' in Conversations Between Parents and Children About Ovarian Cancer
April 10, 2019 – Ryan H. Mitstifer Walton
More Research is Needed to Prevent Late-Stage Diagnosis of Ovarian Cancer
April 08, 2019 – Paula Anastasia RN, MN, AOCN
'Hoping for a Cure, Advocating for Care': COA's Patient Advocacy Initiative
April 05, 2019 – Rose Gerber
Organization Matches Survivors and Caregivers with 'Mentor Angels'
April 03, 2019 – Jonny Imerman
Optune User Journey: Meet Steve
April 01, 2019 – Sponsored Content
Male Breast Cancer Survivor Spreads Awareness: 'Men Have Breasts, Too!'
March 29, 2019 – Sam Rivera
Opening the Door to Communication with Children About Genetic Mutations
March 27, 2019 – Shannon Pulaski
Thanks to Immunotherapies, the Outlook for Patients with RCC is Changing
March 25, 2019 – Mario Snozl, M.D.
The Future of Immunotherapy for Bladder Cancer
March 14, 2019 – Arjun V. Balar, M.D.
Advanced Lung Cancer Outlook Is Better Than Before
February 02, 2019 – Mark Socinski, M.D.
Small Actions Make a Big Difference in the MPN Community
January 30, 2019 – Jean Diesch
Immunotherapy Side Effects: Know the Risks
January 29, 2019 – Jarushka Naidoo, M.B.B.Ch.
Immunotherapy Pair Good for Some, Not All, With Kidney Cancer
January 25, 2019 – Sumanta K. Pal, M.D.
Turning Love for Family Into Cancer Research
January 24, 2019 – Celia Miltz
Expert Discusses Exciting Advances in the MPN Field
January 23, 2019 – Angela Fleischman, M.D., Ph.D.
A PSA for Myeloproliferative Neoplasms
January 22, 2019 – Richard French
A Cure Is Needed for MPNs, says 12-Year-Old
January 21, 2019 – Jaden Persaud
Early Treatment for Myelodysplastic Syndrome: Many Patients Are Missing Out
January 15, 2019 – Christopher Cogle, M.D.
It's an Exciting Time for Myelodysplastic Syndrome
January 11, 2019 – Amy DeZern, M.D.
Cure: Is it Possible for CLL?
January 09, 2019 – John C. Byrd, M.D.
Not the 'Typical Cancer Patient'
January 08, 2019 – Katherine Heinowitz
Knowledge Is Key in Patient Advocacy
January 07, 2019 – Marcy Worthington
Physician Turns Personal Diagnosis to Educational Opportunity
January 04, 2019 – Brian Koffman, M.D.C.M
A Calling to Help Patients With MPNs
January 03, 2019 – Lori Jemison, RN
From Dancing to Amputation and Back Again
January 02, 2019
Scott Hamilton Talks Proton Therapy
December 20, 2018 – Scott Hamilton
Putting Life Into Perspective After a Cancer Diagnosis
December 18, 2018 – Chuck Pagano
Nutrition Is Essential Through the Cancer Journey
December 12, 2018
Myeloma Takeaways from the GRIFFIN Trial
December 11, 2018 – Peter Voorhees, M.D.
Genetic Testing for GI Cancers: Preventative and Diagnostic
December 10, 2018 – Matthew Yurgelun, M.D.
The Basics of Interventional Clinical Trials
December 07, 2018 – William P. Harris, M.D.
Learning the Lingo of Cancer
December 04, 2018 – Shannon Pulaski
Defying Odds and Dancing Through Cancer
November 30, 2018 – Evan Ruggiero
Focusing on Quality of Life, Improving Outcomes in Ovarian Cancer
November 27, 2018 – Maurie Markman, M.D.
Expert Talks Side Effects of PV Treatment
November 21, 2018 – Srdan Verstovsek, M.D., Ph.D.
Clinical Trials: Know the Basics
November 19, 2018 – Ghassan K. Abou-Alfa, M.D.
Advice for Patients: Navigating the Cost of Cancer
November 16, 2018 – Bill Wimbiscus
The Three Steps of Genetic Testing
November 14, 2018 – John Hopper
The Sugar-Cancer Connection
October 31, 2018
Banding Together to Fight Breast Cancer
October 30, 2018
Post-Mastectomy Tattooing: A Personal Decision
October 29, 2018
The Biggest Cosmic Joke: Keeping Your Sense of Humor During Cancer
October 17, 2018 – Maria Falzone
Know Your Family's Health History
October 12, 2018
Barbells for Boobs: Taking Action Against Breast Cancer
October 10, 2018
A Message From Amy Robach on Breast Cancer Awareness Month
October 09, 2018 – Amy Robach
There's Only One Time to Treat Cancer the First Time
October 05, 2018 – Maggie Row, M.D.
Lung Cancer Living Room Brings Patients Together
October 04, 2018 – David LeDuc
Expert Advice for Newly Diagnosed Patients
October 03, 2018 – Leonard Gomella, M.D.
Introducing a Genomic Era in ET
September 27, 2018 – Laura Michaelis, M.D.
Finding Inspiration at the Biden Cancer Summit
September 25, 2018
Granting Wishes for Pediatric Patients
September 21, 2018 – Tom Weatherall
Got Colon Cancer? Get Your Tumor Tested
September 18, 2018 – Thomas K. Weber, M.D., FACS
A Word from Patrick Dempsey During National Ovarian Cancer Awareness Month
September 14, 2018 – Patrick Dempsey
Using the BARF Scale to Measure Nausea
September 11, 2018 – Elizabeth Davis, B.S.N., RN, CPN
Finding the Right Therapy for High-Risk Mantle Cell Lymphoma
September 07, 2018 – Bijal D. Shah, M.D.
Dr. Jeff Young: From Practitioner to Patient
August 22, 2018 – Dr. Jeff Young
Exciting Advancements for Rare Blood Diseases
August 21, 2018 – Kathleen Weis, CEO
Diagnosed With Liver Cancer? See a Specialist
August 14, 2018 – Andrea J. Wilson
Caring for a Young Person With Cancer Can Be a Balancing Act
August 10, 2018 – Nancy Bell
A Chat With Bonnie J. Addario
August 03, 2018 – Bonnie J. Addario
Supporting the Oncology Nurses Who Support Patients
August 01, 2018 – Christine Stone, MSN, RN, OCN
What to Expect When Going on a PARP Inhibitor for Ovarian Cancer
July 31, 2018 – Ursula A. Matulonis, M.D.
The Curative Potential of CAR-T Cell Therapy in Mantle Cell Lymphoma
July 26, 2018 – Andre Goy, M.D., M.S.
When to Treat Relapsed Myeloma
July 24, 2018 – Sagar Lonial, M.D.
Advice for Newly-Diagnosed Ovarian Cancer: You Control Your Life
July 23, 2018
Managing Hypertension and Thyroid Cancer
July 18, 2018 – Lori J. Wirth, M.D.
Expanding Lynch Syndrome Testing Across Tumor Types
July 16, 2018 – Alicia Latham Schwark, M.D.
CAR T-Cell Therapy Offers Hope in DLBCL
July 10, 2018 – Peter Borchmann, M.D.
It's an Exciting Time for Mantle Cell Lymphoma
July 09, 2018 – Michael Wang, M.D.
Deciding Best Next Steps in Prostate Cancer Treatment
July 05, 2018 – Matthew R. Cooperberg, M.D., M.P.H.
Overcoming Barriers and Stigma as a Young Patient
July 03, 2018 – Taylor Bell Duck
Prostate Cancer: To Treat or Not to Treat
June 27, 2018 – Howard Soule, Ph.D.
Exploring Another Biomarker in Ovarian Cancer
June 26, 2018 – David O'Malley, M.D.
Colorectal Cancer Makeup May Differ by Age Group
June 25, 2018 – Aaron Franke, M.D.
Comparing Two MPN Drugs
June 21, 2018 – Trine Alma Knudsen, M.D.
When Facing Metastatic Prostate Cancer, Know What to Ask Your Doctor
June 20, 2018 – Jan Manarite
Participating in a Lung Cancer Registry Can Be Empowering
June 19, 2018 – Sandra Shaw
Don't Write Off Immunotherapy in Brain Cancer Just Yet
June 18, 2018 – David Reardon, M.D.
Building Resiliency in the World of Oncology
June 14, 2018 – Thomas A. Gallo, MS, MDA
Advocacy Groups Collaborate in the Fight Against Prostate Cancer
June 12, 2018 – Mike Crosby
PD-L1: An Important, But Imperfect Biomarker
June 11, 2018 – H. Jack West, M.D.
Patients With CRC: Advocate to Have Your Tumor Tested
June 08, 2018 – Sarah DeBord
Focusing on Improving Depression in HNC Survivors
June 07, 2018 – Nosayaba Osazuwa-Peters, BDS, MPH, CHES
Survivor Discusses Exciting Advancements in Prostate Cancer
June 07, 2018 – Terry Fischer
Two-Drug Combo Improves Post-Transplant Myeloma Outcomes
June 06, 2018 – Loretta Williams
Expert Discusses the Evolving Field of Gynecologic Cancers
June 05, 2018 – Maurie Markman, M.D.
Vitamin D Deficiencies Can Impact Myeloma Outcomes
May 30, 2018 – Chloe Spear, BSN, RN, OCN
Facing Challenges and Excitement for Immunotherapy in GI Cancers
May 29, 2018 – Gregory L. Beatty, M.D., Ph.D.
Helping Patients Navigate the Clinical Trial Space
May 27, 2018 – Karen DeMairo
Finding Your Fight Mode After a Cancer Diagnosis
May 23, 2018 – Barbara Abernathy, Ph.D.
Examining Stress and Quality of Life in Bladder Cancer
May 21, 2018 – Ahrang Jung
Spotting the Signs of Uterine Cancer
May 11, 2018 – Dennis R. Scribner, M.D.
Debunking Clinical Trial Myths
April 23, 2018 – Laurel W. Rice, M.D.
There Are Multiple Dynamic Biomarkers for Bladder Cancer
April 20, 2018 – Padmanee Sharma, M.D., Ph.D.
Patrick Dempsey on Complementary Therapies
April 17, 2018 – Patrick Dempsey
The Benefits of Jakafi for Patients With PV
April 10, 2018 – Jeanne M. Palmer, M.D.
Raising Funds for Brain Tumors Until Poof! They Disappear
April 06, 2018 – Thea's Star of Hope
Genetic Testing Is Important for Both Patients and Family Members
March 19, 2018 – John Marshall, M.D.
Expert Discusses Surgical Implications of a BRCA Mutation
March 15, 2018 – William J Gradishar, M.D.
CAR-T Cell Therapy: It's Astonishing
March 14, 2018 – Jane N. Winter, M.D.
Understanding Immunotherapy's Side Effects
March 13, 2018 – Jarushka Naidoo, MBBCh
Distinguishing Myeloma from Smoldering Myeloma
March 12, 2018 – Sagar Lonial, M.D.
Colorectal Cancer Awareness Month: 'We Have Work to Do'
March 09, 2018 – John Marshall, M.D.
Complementary Therapy and Exercise in Patients With MPNs
March 07, 2018 – Ruben Mesa, M.D.
Exploring Therapeutic Vaccine in Head and Neck Cancer
February 26, 2018 – Joshua Bauml, M.D.
Combining and Sequencing Agents in CLL
January 30, 2018 – William G. Wierda, M.D., Ph.D.
Giving Patients Autonomy During Difficult Conversations
January 26, 2018 – Joshua Richter, M.D.
MSI Testing Is Crucial in Colorectal Cancer
January 23, 2018 – Michael J. Overman, M.D.
Statistics Do Not Predict Patients' Fate
January 22, 2018 – Tom Stockwell
Lymphoma Expert Suggests Asking About Clinical Trials Soon After Diagnosis
January 21, 2018 – Radhakrishnan Ramchandren, M.D.
Immunotherapy Brings 'Radical Change' to Lung Cancer Treatment
January 19, 2018 – Marina Chiara Garassino, M.D.
What Makes People with Myeloproliferative Neoplasms Unique?
January 19, 2018 – Carole Brennan Miller, M.D.
How To Support Loved Ones With Myeloproliferative Neoplasms
January 17, 2018 – Julie R. Libon
The Evolution of PARP Inhibitors in Ovarian Cancer
January 15, 2018 – Cristiana Sessa, M.D.
Connecting the Science to the Patient
January 13, 2018 – Susan Leclair, Ph.D., CLS (NCA)
Most Common Myth About Clinical Trials
January 12, 2018 – Catriona Jamieson, M.D., Ph.D.
Examining Response Rates in MSI-H and NTRK Fusion GI Cancers
January 10, 2018 – Luis A. Diaz, M.D.
Should Patients Conduct Online Research About Their Diagnosis?
January 09, 2018 – Mark Heaney, M.D., Ph.D.
What to Know When Choosing Between Treatments for Myeloproliferative Neoplasms
January 08, 2018 – Catriona Jamieson, M.D., Ph.D.
Managing Symptoms For Patients With Myeloproliferative Neoplasms
January 06, 2018 – Gabriela Hobbs, M.D.
Comprehensive Visits Following MPN Diagnosis Is Critical
January 05, 2018 – Lindsey M. Lyle, M.S.
Redefining Hope and Finding Inspiration From Children
January 04, 2018 – Barbara Abernathy, Ph.D.
Giving a Voice to Patients With GI Cancers
January 03, 2018 – Martha Raymond
Julie Nangia Discusses the Impact of Hair Loss
December 21, 2017 – Julie Nangia, M.D.
Diagnostic Advances Shape Treatment Decisions in Lung Cancer
December 19, 2017 – David R. Gandara, M.D
Looking Ahead: Ovarian Cancer Hopes for 2018
December 18, 2017 – Oliver Dorigo, M.D., Ph.D.
Preserving Fertility and Improving Outcomes in Breast Cancer
December 13, 2017 – Halle Moore, M.D.
Striving for Better Ovarian Cancer Screening Methods
December 11, 2017 – Oliver Dorigo, M.D., Ph.D.
Ovarian Cancer Developments in 2017
December 06, 2017
Stay Informed and Healthy During Cancer
November 28, 2017 – Anya Khomenko
Advice for Survivors on Dealing With Sexual Issues
November 16, 2017 – Michael Krychman, M.D.
A Smile Could Mean the World to Someone With Cancer
November 15, 2017 – Jim Kelly
Combining Local and Systemic Therapies in Liver Cancer
November 14, 2017 – Ghassan K. Abou-Alfa, M.D.
The Importance of Shared Decision Making in Cancer Care
November 02, 2017 – Thomas Butler, M.D.
Bringing Quality Cancer Care Closer to Home
November 01, 2017 – Edward S. Kim, M.D.
Understanding Cancer's Financial Landscape
October 30, 2017 – Ashley Johnson
Implementing a Mobile Lung Cancer Screening Unit
October 27, 2017 – Mellisa Wheeler
Addressing the Needs of Older Patients With Cancer
October 26, 2017 – Janine Overcash, Ph.D.
Building Community Partnerships to Improve Cancer Outcomes
October 25, 2017 – Nadine Barrett, Ph.D.
Breaking Down Misconceptions About Glioblastoma
October 13, 2017 – David Reardon, M.D.
Preserving Eyebrows During Chemotherapy Treatment
October 11, 2017 – Renata Marie Vestevich
Expert Discusses Exciting Advances in Ovarian Cancer
October 05, 2017 – Rebecca Arend, M.D.
Does Age Affect Cancer Genomics?
October 04, 2017 – Garett Frampton
Facing Advanced Cancer's Struggles With CALM
October 03, 2017 – Gary Rodin, M.D.
When to Stop Immunotherapy Treatment for Melanoma
October 02, 2017 – Yania Jansen
Advice for Newly Diagnosed Patients With GBM
September 27, 2017 – David Reardon, M.D.
Expert Urges Patients to Speak Up About Treatment Side Effects
September 19, 2017 – Jeffrey Weber, M.D., Ph.D.
The Importance of Seeing an Ovarian Cancer Specialist
September 15, 2017 – Renee Cowan
Author Talks About the Steps Leading Up to His Cancer Diagnosis
September 13, 2017 – Michael D. Becker
Developing a Patient-Friendly Clinical Trial Search Engine
September 11, 2017 – Kathryn Burn
Words of Wisdom for Patients With Liver Cancer
September 08, 2017 – Andrea J. Wilson
Newly Discovered Biomarker May Help Personalize Colorectal Cancer Treatment
September 07, 2017 – Martin D. Berger, M.D.
Cancer Statistics and Outcomes Differ by Zip Code
September 07, 2017 – Gary A. Puckrein, Ph.D.
Treatment Transport Helps Patients Keep Their Appointments
September 06, 2017 – Lauren Belive
Data Sharing Is Critical in Advancing Cancer Care
September 05, 2017 – Kathleen Gallagher
The Importance of Early Detection in Cancer Care
September 01, 2017 – Beth Meagher
The CDC's Role in the National Cancer Moonshot Initiative
August 31, 2017 – Lisa Richardson, M.D., M.P.H.
Mapping Out the Care Team in Cancer Survivorship
August 30, 2017 – Patricia J. Goldsmith
Hopes for the Future of Cancer Care
August 29, 2017 – Jeff Allen
Keeping Momentum on the Cancer Moonshot Initiative
August 28, 2017 – Elizabeth Jaffee, M.D.
The Importance of Diverse Clinical Trials in Cancer
August 21, 2017 – Donna Cryer
Examining the Role of Stress in Lung Cancer
August 16, 2017 – Syed Jafri, M.D.
Dr. Boulay Discusses Removing a 140-Pound Tumor
August 15, 2017 – Richard Boulay, M.D.
The Importance of a Multidisciplinary Team in Building Bladder Cancer Guidelines
July 27, 2017 – Jeffrey Holzbeierlein, M.D.
Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines
July 27, 2017 – Johnathan E. Rosenberg, M.D.
Chris Draft on What Caregivers Should Know
July 27, 2017 – Chris Draft
The Cancer Moonshot and Parker Institute for Cancer Immunotherapy
July 26, 2017 – Ramy Ibrahim, M.D.
Examining Quality of Life Issues for Patients With MPNs
July 25, 2017 – Sandra Allen-Bard
The Unique Struggles of Women With Ovarian Cancer
July 24, 2017 – Fay J. Hlubocky, Ph.D., M.A.
Greg Simon on the Biden Cancer Initiative
July 17, 2017 – Greg Simon
Mindy Mintz Mordecai on the Association Between Acid Reflux and Esophageal Cancer
July 14, 2017 – Mindy Mintz Mordecai
Filling an Unmet Need in MDS Treatment
July 07, 2017 – Rami S. Komrokji, M.D.
Axel Hoos on the ATOM Initiative
July 06, 2017 – Axel Hoos, M.D., Ph.D.
Juergen Klenk on the Cancer XPRIZE
July 06, 2017 – Juergen Klenk
Recognizing the Importance of Cancer Prevention
June 29, 2017 – Carolyn R. Aldige
Cancer Survivor Celebrates by Dancing with Scripps Doctor
June 28, 2017 – Irene Hutchins, M.D., and her patient Steve Valentine,
Patrick Dempsey Talks Cancer
June 27, 2017 – Patrick Dempsey
Dr. Len Answers: What Is the Best Anti-Cancer Diet?
June 23, 2017 – Len Lichtenfeld, M.D.
Using an App to Reduce Cancer-Related Anxiety
June 21, 2017 – Joseph Greer, Ph.D.
Patrick Dempsey Discusses the Dempsey Center
May 30, 2017 – Patrick Dempsey
Moving Mountains for Multiple Myeloma Kilimanjaro 2017
May 11, 2017
CURE Media Group Colorectal Cancer Awareness Month Educational Video Series
March 28, 2017
Jim Kelly on Dealing With Pain and Staying Motivated
March 09, 2017 – Jim Kelly
Changing Melanoma Treatment in 2017
February 22, 2017
Make a Difference Today for Someone Fighting for Their Tomorrow
February 03, 2017 – Jim Kelly
Jim Kelly Discusses His Cancer Diagnosis
January 31, 2017 – Jim Kelly
Andrew Schorr on How Journalism Led Him to Patient Advocacy
January 18, 2017 – Andrew Schorr
What's Exciting in the Field of MPNs?
January 12, 2017 – Ross L. Levine, M.D.
Elliott Winton on the Changing Landscape of MPN Treatment
January 11, 2017 – Elliott Winton, M.D.
Patricia K. Koenig: Living With Polycythemia Vera
January 09, 2017 – Patricia K. Koenig
Using Social Media to Recruit for Cancer Clinical Trials
January 06, 2017 – Alicia Staley
MM4MM 2017 Kilimanjaro Team Training Climb
January 05, 2017 – Moving Mountains for Multiple Myeloma
Miracles Do Happen in GBM
January 05, 2017 – Dellann Elliott Mydland
Educating Patients to Ensure the Best MPN Care
January 04, 2017 – Erin H. Blackwell
Fran Drescher: Living "Old School" to Prevent Cancer
December 30, 2016 – Fran Drescher
Bonnie J. Blankert on Being a Caregiver to Someone With an MPN
December 29, 2016 – Bonnie J. Blankert
Sam Smith Explains Cognitive Behavioral Therapy for Patients With Breast Cancer
December 28, 2016 – Sam Smith
David Wallace on Being Your Own Cancer Advocate
December 28, 2016
Gary Mervis on Putting Cancer on the "Front Burner"
December 23, 2016 – Gary Mervis
Ann Brazeau on the Importance of MPN Support Groups
December 21, 2016 – Ann Brazeau
Sumul Raval Tells Patients With GBM, "I'm Your Quarterback"
December 14, 2016 – Sumul Raval, M.D.
Siddhartha Mukherjee on Increasing MPN Awareness
December 12, 2016 – Siddhartha Mukherjee, M.D., Ph.D.
What's Next in Immunotherapy?
December 02, 2016 – Christian M. Capitini, M.D.
Personalized Cancer Care Plans in the Age of "Dr. Google"
November 29, 2016 – Ann Culkin, R.N., O.C.N.
Beth Sandy on Managing Chemotherapy-Induced Nausea
November 28, 2016 – Beth Sandy, C.R.N.P
Treatment-Related Side Effects in Breast Cancer Survivors
November 23, 2016 – Halle Moore, M.D.
Using Body Composition to Dose Cancer Treatment
November 21, 2016 – Grant Williams, M.D.
Jennifer Klemp Asks Unanswered Questions in Breast Cancer Survivorship
November 17, 2016 – Jennifer Klemp, Ph.D., M.P.H.
Gary Shelton Addresses Myths About Palliative Cancer Care
November 14, 2016 – Gary Shelton, Ph.D.
Chuck Wakefield Discusses Training for the Kilimanjaro Climb
November 11, 2016 – Chuck Wakefield
Moving Mountains for Multiple Myeloma: The Machu Picchu Climb
November 02, 2016
The Moving Mountains for Multiple Myeloma Machu Picchu Full Documentary
November 02, 2016
Moving Mountains for Multiple Myeloma: The Machu Picchu Climb
October 21, 2016
Raghav Sundar on Preventing CIPN
October 19, 2016 – Raghav Sundar, M.B.B.S., M.R.C.P., M.Med.
What to Know: Managing Side Effects on Immunotherapy
October 05, 2016 – Winson Cheung, M.D.
Matthew Galsky Gives an Overview of Bladder Cancer
September 30, 2016 – Matthew Galsky, M.D.
Mark Malkin Discusses Using Viruses to Treat Brain Cancer
September 29, 2016 – Mark Malkin, M.D.
The Benefits of Falun Gong for Patients With Cancer
September 08, 2016 – Yuhong Dong, M.D., PhD
Choosing the Right Diet in Breast Cancer Survivorship
August 31, 2016 – Nathalie LeVasseur
A 200-Mile Run for Multiple Myeloma
August 30, 2016 – Eric Gelber
Ishwaria Mohan Subbiah on Older Patients Enrolled in Clinical Trials
August 24, 2016 – Ishwaria Mohan Subbiah
Supriya Mohile on Discussing Worries With the Doctor
August 23, 2016 – Supriya Mohile
Fatigue or Autoimmune Disease? Physician Talks Immunotherapy Side Effects
August 19, 2016 – Yvonne Saenger, MD
The Importance of Patient Education in Breast Reconstruction
August 16, 2016 – Ricardo J. Bello
The Surprising Benefit of Soybean Oil for Patients With Breast Cancer
August 12, 2016 – Luke Peppone
Halle Moore on Fatigue in Breast Cancer Survivors
August 11, 2016 – Halle Moore
Ronald Natale on Treatment Options for EGFR-Mutant Lung Cancer
August 08, 2016 – Ronald Natale
Karuppiah Kannan on the Past and Future of Myeloma Treatment
August 04, 2016 – Karuppiah Kannan
What to Consider Before Choosing a Melanoma Treatment Plan
August 03, 2016 – Claire Friedman, MD
Patient-to-Patient: What to Expect in a Clinical Trial
August 02, 2016 – Janet Freeman-Daily
Bridging the Researcher-Patient Gap
July 29, 2016 – Karuppiah Kannan
Kelly Kenzik Talks Racial Disparities in Breast Cancer Survivorship
July 27, 2016 – Kelly Kenzik, MS, PhD
Barbara Van Husen on Improvements in MPN Research
July 27, 2016 – Barbara Van Husen
Moaath K. Mustafa Ali on the Effects of Smoking for Breast Cancer Survivors
July 25, 2016 – Moaath K. Mustafa Ali, MD
Highlights From the 2016 Multiple Myeloma Heroes Event
July 22, 2016 – Multiple Myeloma Heroes
Highlights From Our Events
July 21, 2016 – CURE staff
Emily Johnston Discusses End-of-Life Care for Younger Patients
July 21, 2016 – Emily Johnston, MD
Using Exercise to Reduce Both Depression and Health Disparities
July 20, 2016 – Charles Kamen
Highlights From the 2016 Extraordinary Healer Award Event
July 12, 2016 – Extraordinary Healer
Beth DuPree on What Patients With Breast Cancer Need to Know at Diagnosis
July 07, 2016 – Beth DuPree, MD, FACS, ABIHM
Jennifer Arnold on the Importance of Listening
June 27, 2016 – Jennifer Arnold
Greg Cantwell on the Importance of Hope When Facing a GBM Diagnosis
June 23, 2016 – Greg Cantwell
Carmi Fazio on End-of-Life Cancer Care
June 21, 2016 – Carmi Fazio, RN, MSN, ONA
Diana Gordon on Dealing With Insurance Companies
June 15, 2016 – DIANA GORDON, RN, MSN, CPNP, CPON
Lee Schwartzberg on Nausea Concerns for Newly Diagnosed Patients
June 10, 2016 – Lee Schwartzberg, MD, FACP
Carmi Fazio on Helping Patients Cope With Their Cancer
June 07, 2016 – Carmi Fazio, RN, MSN, ONA
Celestia S. Higano on Sexual Health and Pelvic Floor Physiotherapy
June 07, 2016 – Celestia S. Higano
Nathalie Le Vasseur on a Review of Optimal Weight Control Strategies
June 05, 2016 – Nathalie Le Vasseur
Depression Among Patients With Cancer
June 04, 2016 – Uri Goldberg, MD
Lynne Joy Malestic Discusses Her Transition to Oncology Nursing
June 03, 2016 – Lynne Malestic, RN
Our Trip to the Grand Canyon to Raise Money for Cancer Research
June 02, 2016 – Marty Murphy
Diana Gordon on the Typical Day of a Pediatric Oncologist
June 01, 2016 – DIANA GORDON, RN, MSN, CPNP, CPON
Carmi Fazio on the Power of Oncology Nurses
May 25, 2016 – Carmi Fazio, RN, MSN, ONA
Diana Gordon on Caring for Children With Cancer
May 09, 2016 – Diana Gordon, RN, MSN, CPNP, CPON
Lynne Joy Malestic Discusses Caring For a Couple With Cancer
May 04, 2016 – Lynne Joy Malestic, RN
Eric Stonestreet on His Passion for Cancer Advocacy
May 02, 2016 – Eric Stonestreet
Rafat Abonour on the Importance of Raising Awareness About Myeloma
April 06, 2016 – Rafat Abonour
Mary Bohn on the Landscape of Multiple Myeloma Treatment
April 06, 2016 – Mary Bohn
Alicia O'Neill on How Everyone Can Make a Difference in Myeloma
April 06, 2016 – Alicia O'Neill, Multiple Myeloma Research Foundation
Jenny Ahlstrom on How Patients Can Help to Find a Multiple Myeloma Cure
April 06, 2016 – Jenny Ahlstrom
Multiple Myeloma Hero Chuck Wakefield on Patients Inspiring Other Patients
April 05, 2016 – Chuck Wakefield
Ryan Cohlhepp on the Accomplishments of the Moving Mountains Team
April 05, 2016 – Ryan Cohlhepp
Jeff Goad on Climbing Mount Kilimanjaro for Myeloma Research and Awareness
April 04, 2016 – Jeff Goad
Stan Wagner on the Determination to Reach Mt. Kilimanjaro's Summit
April 04, 2016 – Stan Wagner, Multiple Myeloma Hero
Jason Katz on His Father's Love For Helping Others With Multiple Myeloma
April 01, 2016 – Jason Katz
Bob Dickey on the Value of Relationships From Climbing Mount Kilimanjaro
March 31, 2016 – Bob Dickey, Multiple Myeloma Hero
Marlee Matlin Discusses Her Father's Diagnosis of Multiple Myeloma
March 24, 2016 – Marlee Matlin
Susan Melvin Hill Tells Her MPN Story and Discusses Patient Advocacy
March 23, 2016 – Susan Melvin Hill
Jason R. Gotlib on JAK Inhibitors for the Treatment of Myelofibrosis
March 22, 2016 – Jason R. Gotlib
Kareem Abdul-Jabbar Provides Advice for a Newly Diagnosed CML Patient
March 18, 2016 – Kareem Abdul-Jabbar
David Dubin Provides Advice to Lynch Syndrome Previvors
March 18, 2016 – David Dubin
Amy Robach on How to Take Control of Your Breast Cancer Care
March 14, 2016 – Amy Robach
On Cancer, Lynch Syndrome and Soccer
February 29, 2016 – David Dubin
Pioneering Oncologist Provides an Overview of Advances in Cancer
February 25, 2016 – Maurie Markman and Vincent T. DeVita
Pioneering Oncologist Discusses Preventing Cancer
February 25, 2016 – Maurie Markman and Vincent T. DeVita
Pioneering Oncologist on Curing Cancer
February 25, 2016 – Maurie Markman and Vincent T. DeVita
Pioneering Oncologist Discusses "The Death of Cancer"
February 25, 2016 – Maurie Markman and Vincent T. DeVita
Danielle Friedman on a Study of Diabetes Among Childhood Cancer Survivors
January 29, 2016 – Danielle Novetsky Friedman
Kevin C. Oeffinger on Tailoring Survivorship Care
January 28, 2016 – Kevin C. Oeffinger
Danielle Nicosia on Being Misdiagnosed
January 25, 2016 – Danielle Nicosia
Mary McCabe on the Need for Personalized Survivorship Care
January 16, 2016 – Mary McCabe
Jessica Safran Provides Advice on Picking a Wig After Chemotherapy
January 12, 2016 – Jessica Safran
Kay Verble Discusses a Study to Characterize Long-Term Survivors of GBM
January 06, 2016 – Kay Verble
Karen Duffy Pays Tribute to One of Our MPN Heroes
December 23, 2015 – Karen Duffy
Greg Cantwell on Supporting and Educating GBM Patients
December 22, 2015 – Greg Cantwell
Jason R. Gotlib Discusses MPN Research at Stanford
December 22, 2015 – Jason R. Gotlib
David T. Boule on the Challenges and Rewards of Patient Advocacy
December 22, 2015 – David T. Boule
Sherry Fox on What It Means to Be a GBM Hero
December 21, 2015 – Sherry Fox
Santosh Kesari on Thinking Outside the Box in GBM Research
December 21, 2015 – Santosh Kesari
Rebecca N. Claassen on the Importance of Educating Nurses About MPNs
December 21, 2015 – Rebecca N. Claassen
Susan Melvin Hill on Supporting MPN Patients in Idaho
December 21, 2015 – Susan Melvin Hill
Barbara Van Husen on Past, Present and Future MPN Research
December 21, 2015 – Barbara Van Husen
David Allen Denny Tells His MPN Story
December 21, 2015 – David Allen Denny
What You Should Know About Cord Blood Banking
December 18, 2015 – Consumer Affairs
Blake A. Morrison Discusses the Excitement in Myeloma Research
December 09, 2015 – Blake A. Morrison
Jennifer Arnold Pays Tribute to Our MPN Heroes
December 08, 2015 – Jennifer Arnold
Valerie Harper Pays Tribute to Our GBM Heroes
December 01, 2015 – Valerie Harper
William G. Wierda on the Treatment of CLL
November 30, 2015 – William G. Wierda
Mark R. Gilbert Discusses Glioblastoma Research
November 30, 2015 – Mark R. Gilbert
Michael J. Mauro on Questions From Patients With CML
November 18, 2015 – Michael J. Mauro
Michael J. Mauro Discusses the Diagnosis of CML
November 18, 2015 – Michael J. Mauro
Diagnosing and Treating Smoldering Multiple Myeloma
November 09, 2015 – C. Ola Landgren
Measuring Response to Treatment in Multiple Myeloma
November 09, 2015 – C. Ola Landgren
Alison Morris on the Future of Screening for Distress
October 27, 2015 – Alison Morris
Alison Morris on Screening for Emotional and Physical Distress
October 27, 2015 – Alison Morris
Case Study of a 33-Year-Old With Metastatic Colorectal Cancer
October 20, 2015 – David Liu
Rudolph Navari on Preventing CINV With Olanzapine
October 19, 2015 – Rudolph Navari
Christian J. Nelson on Quality of Life Among Patients With Cancer
October 07, 2015 – Christian J. Nelson
Christian J. Nelson Discusses the Treatment of Older Patients With Cancer
October 07, 2015 – Christian J. Nelson
Amanda L. Kong on Seeking a Second Opinion for Breast Cancer Care at a High Volume Hospital
October 06, 2015 – Amanda L. Kong
Amanda L. Kong on Breast Cancer Care at High Volume Hospitals
October 06, 2015 – Amanda L. Kong
Carolyn Presley on the Implications of Screening on Lung Cancer Care
October 02, 2015 – Carolyn Presley
Carolyn Presley Discusses the Burden of Curative Lung Cancer Treatment
October 02, 2015 – Carolyn Presley
Aziz Nazha on Adverse Events Associated With Treatment for MDS
September 30, 2015 – Aziz Nazha
Aziz Nazha Discusses the Future of Treating Patients With MDS
September 30, 2015 – Aziz Nazha
Bethany Andrews Rhoten on How Patients Can Cope With Body Image Issues
September 29, 2015 – Bethany Andrews Rhoten
Bethany Andrews Rhoten on Body Image Issues Among Patients With Head and Neck Cancer
September 29, 2015 – Bethany Andrews Rhoten
Andrew M. Kaunitz on Side Effects From Surgically-Induced Menopause
September 28, 2015 – Andrew M. Kaunitz
Andrew M. Kaunitz on Bioidentical Hormone Therapy
September 28, 2015 – Andrew M. Kaunitz
Anees B. Chagpar on What to Expect After Contralateral Prophylactic Mastectomy
September 25, 2015 – Anees B. Chagpar
Anees B. Chagpar Provides an Overview of Contralateral Prophylactic Mastectomy
September 25, 2015 – Anees B. Chagpar
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
September 24, 2015 – Lecia V. Sequist
Lecia V. Sequist Provides an Overview of T790M Mutations in NSCLC
September 24, 2015 – Lecia V. Sequist
Sharon L. Bober on the Importance of Maintaining Sexual Health After Cancer
September 23, 2015 – Sharon L. Bober
Sharon L. Bober on Sexual Health Changes in Relation to Treatment
September 23, 2015 – Sharon L. Bober
Shaji Kumar on Later Lines of Treatment for Myeloma
September 22, 2015 – Shaji Kumar
Shaji Kumar on Treatment-Related Adverse Events From Monoclonal Antibodies
September 22, 2015 – Shaji Kumar
Marianne Davies on Immunotherapy-Related Side Effects in Lung Cancer
September 21, 2015 – Marianne Davies
Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer
September 18, 2015 – Sara M. Tolaney
Ginny Finn on the Importance of Addressing Breast Cancer Survivorship Issues
September 16, 2015 – Ginny Finn
Jacquelyn Powers on Empowering Patients With Information Regarding Genetic Testing
September 15, 2015 – Jacquelyn Powers
Jacquelyn Powers on When Individuals Should Consider Genetic Testing
September 15, 2015 – Jacquelyn Powers
Gregory J. Riely on the Identification and Treatment of MET Exon 14 Skipping Mutations
September 14, 2015 – Gregory J. Riely
Gregory J. Riely on MET Exon 14 Skipping Mutations in Lung Cancer
September 14, 2015 – Gregory J. Riely
Kim Statham Ringen on the Importance of Meeting Other Survivors
September 11, 2015 – Kim Statham Ringen
Kim Statham Ringen on the Stigma of Lung Cancer
September 11, 2015 – Kim Statham Ringen
Debra Patt on the Challenges of Enrolling in the Health Insurance Marketplace
September 04, 2015 – Debra Patt
Debra Patt Discusses the Impact of Health Care Reform on Patients
September 04, 2015 – Debra Patt
Fred R. Hirsch Discusses His Own Cancer Diagnosis
September 03, 2015 – Fred R. Hirsch
Bonnie J. Addario Discusses the Genomics of Young Lung Cancer Study
September 03, 2015 – Bonnie J. Addario
Susan Krigel on the Effect of Fear of Recurrence on Quality of Life
September 02, 2015 – Susan Krigel
Susan Krigel Discusses Fear of Recurrence Among Cancer Survivors
September 02, 2015 – Susan Krigel
Michelle Esser Discusses Two Encouraging Breast Cancer Studies
September 01, 2015 – Michelle Esser
Anjee Davis on the Future of Research and Advocacy in Colorectal Cancer
August 31, 2015 – Anjee Davis
Jill Stopfer on the Limitations of Multigene Panel Testing
August 28, 2015 – Jill Stopfer
Jill Stopfer on the Benefits of Multigene Panel Testing
August 28, 2015 – Jill Stopfer
Jessica Ryan Discusses Recovery from an Extreme Oncoplasty
August 27, 2015 – Jessica Ryan
Jessica Ryan Provides an Overview of Extreme Oncoplasty
August 27, 2015 – Jessica Ryan
Susan Thornton on Unmet Needs in Cutaneous Lymphoma
August 26, 2015 – Susan Thornton
Susan Thornton on Bridging the Knowledge Gap Between Researchers and Patients
August 26, 2015
Gwendolyn P. Quinn on the Need to Educate Health Care Providers on Reproductive Health
August 25, 2015 – Gwendolyn P. Quinn
Gwendolyn P. Quinn on Infertility Among Survivors of Adolescent and Young Adult Cancers
August 25, 2015 – Gwendolyn P. Quinn
D. Ross Camidge Discusses Brain Metastases in Patients With Lung Cancer
August 24, 2015 – D. Ross Camidge
D. Ross Camidge on the Development of a New Lung Cancer Drug
August 24, 2015 – D. Ross Camidge
Suresh Ramalingam on Toxicities Associated With Immunotherapy in Different Disease Types
August 21, 2015 – Suresh S. Ramalingam
Suresh Ramalingam on Side Effects Associated With Immunotherapy in Lung Cancer
August 21, 2015 – Suresh S. Ramalingam
Mary B. Daly on Men and Their Genetic Risk for Cancer
August 19, 2015 – Mary B. Daly
Hope Rugo on Managing Sexual Dysfunction From Ovarian Suppression
August 18, 2015 – Hope S. Rugo
Hope Rugo on Managing Effects From Ovarian Suppression in Patients With Breast Cancer
August 18, 2015 – Hope S. Rugo
Heidi Gottlieb Gives Advice to Brain Tumor Patients and Survivors
August 17, 2015 – Heidi Gottlieb
Leslie R. Schover on Sexuality After Cancer Treatment
August 11, 2015 – Leslie R. Schover
Leslie R. Schover on Male Issues After Cancer Treatment
August 11, 2015 – Leslie R. Schover
Frederic C. Kass on Dealing With Fear Associated With a Cancer Diagnosis
August 10, 2015 – Frederic C. Kass
Frederic C. Kass on the Importance of Genetic Counseling
August 10, 2015 – Frederic C. Kass
Cokie Roberts on the Importance of Having an Ally at Medical Appointments
August 03, 2015 – Cokie Roberts
Cokie Roberts on Addressing the Whole Person During Treatment
August 03, 2015 – Cokie Roberts
Bonnie J. Addario Discusses Unmet Needs in Lung Cancer Care
July 30, 2015 – Bonnie J. Addario
Melinda Liggett Irwin on Exercise and Fatigue in Women Diagnosed With Ovarian Cancer
July 28, 2015 – Melinda Liggett Irwin
Melinda Liggett Irwin Discusses Fitness After a Cancer Diagnosis
July 28, 2015 – Melinda Liggett Irwin
Janet Freeman-Daily on Genomic Testing for Lung Cancer Patients
July 27, 2015 – Janet Freeman-Daily
Janet Freeman-Daily on Why Patients Should Attend the ASCO Meeting
July 27, 2015 – Janet Freeman-Daily
Paul B. Jacobsen on Preserving Fertility for Patients With Cancer
July 24, 2015 – Paul B. Jacobsen
Paul B. Jacobsen Discusses Fatigue in Cancer Survivors
July 24, 2015 – Paul B. Jacobsen
Photographer Bill Aron Discusses His Book
July 23, 2015 – Bill Aron
Photographer Bill Aron Tells His Prostate Cancer Story
July 23, 2015 – Bill Aron
Patrick I. Borgen on Cancer-Related Pain Relief With Exparel
July 22, 2015 – Patrick I. Borgen
Patrick I. Borgen Discusses Opioids for Treating Cancer-Related Pain
July 22, 2015 – Patrick I. Borgen
Kristen Harris Shares Her Story
July 21, 2015 – Kristen Harris
Adele Croteau Discusses the Impact of Her Mother's Cancer
July 21, 2015 – Adele Croteau
Jyoti D. Patel on Treating Brain Metastases in Lung Cancer Patients
July 20, 2015 – Jyoti D. Patel
Jyoti D. Patel on the Progress of Immunotherapy in NSCLC
July 20, 2015 – Jyoti D. Patel
Kara Maxwell Explains Breast Cancer Clinical Trials
July 10, 2015 – Kara Maxwell
Kara Maxwell Provides Advice for a Patient With Early Stage Breast Cancer
July 10, 2015 – Kara Maxwell
Rep. Frank Pallone Jr. on Streamlining the Anti-Cancer Drug Approval Process
July 10, 2015 – Rep. Frank Pallone Jr.
Rep. Frank Pallone Jr. Discusses the NIH Innovation Fund
July 09, 2015 – Rep. Frank Pallone Jr.
Anya Prince on Insurance Coverage for Preventative Services
July 08, 2015 – Anya Prince
Anya Prince on Insurance Coverage for Preventative Services
July 08, 2015 – Anya Prince
Anya Prince on How Insurance Appeals Can Help a Patient
July 08, 2015 – Anya Prince
Anya Prince on How Insurance Appeals Can Help a Patient
July 08, 2015 – Anya Prince
Kenneth Freundlich on the Importance of Advocacy for Patients With Hereditary Cancers
July 07, 2015 – Kenneth Freundlich
Kenneth Freundlich on Support for Patients With Hereditary Cancers
July 07, 2015 – Kenneth Freundlich
Rebecca Sutphen Discusses Genetic Counseling and Testing
July 06, 2015 – Rebecca Sutphen
Rebecca Sutphen on the Importance of Connecting Patients With Clinical Trials
July 06, 2015 – Rebecca Sutphen
Dana Bushman on the Benefits of Yoga for a Patient With Cancer
July 02, 2015 – Dana Bushman
Dana Bushman on Her Connection to Cancer and Yoga
July 02, 2015 – Dana Bushman
Jennifer Klemp on Survivorship for Patients With Hereditary Breast Cancer
July 01, 2015 – Jennifer Klemp, PhD, MPH
Jennifer Klemp Discusses Breast Cancer Survivorship
July 01, 2015 – Jennifer Klemp, PhD, MPH
Jennifer Klemp Discusses Breast Cancer Survivorship
July 01, 2015 – Jennifer Klemp, PhD, MPH
Sue Friedman on Informed Decision-Making in Hereditary Breast and Ovarian Cancers
June 30, 2015 – Sue Friedman
Sue Friedman on Informed Decision-Making in Hereditary Breast and Ovarian Cancers
June 30, 2015 – Sue Friedman
Melanie A. Nix Discusses the Spectrum of Advocacy
June 29, 2015 – Melanie A. Nix
Dellann Elliott Mydland on Testing Brain Tumor Tissue
June 17, 2015 – Dellann Elliott Mydland
Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer
June 11, 2015 – Debu Tripathy
Rep. Frank Pallone Jr. on the Impetus for the 21st Century Cures Act
June 10, 2015 – Rep. Frank Pallone Jr.
Colleen M. O'Leary on How Patients Can Manage Oral Mucositis
May 29, 2015 – Colleen M. O'Leary, RN, MSN, AOCNS
Patricia Carter on the Importance of Sleep
May 18, 2015 – Patricia Carter, PhD, RN, CNS
Julie Fleshman on the Role of Nutrition in the Life of a Patient With Pancreatic Cancer
May 15, 2015 – Julie Fleshman
Jeannie Woith on the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
May 13, 2015 – Jeannie Woith, BSN, RN, LMT
Dr. Shore Provides an Overview of Biomarkers in Prostate Cancer
May 12, 2015 – Neal D. Shore, MD, FACS
Anne Katz on Young Patients With Cancer and Their Sexuality
May 08, 2015 – Anne Katz, RN, PhD
Michael Ferraro on His Mother's Pancreatic Cancer Journey
May 06, 2015 – Michael Ferraro
Jasmine Martin Discusses Oral Adherence
May 01, 2015 – Jasmine Martin
Sandra Spoelstra, PhD, RN, on Educating Patients About Oral Agents
April 30, 2015 – Sandra Spoelstra, PhD, RN
Amanda Yopp, NP, Discusses Patient Education Regarding Clinical Trials
April 29, 2015 – Amanda Yopp, NP
2015 Extraordinary Healer Award Overview
April 24, 2015
Dr. Primo Lara Discusses Emerging Therapies in Kidney Cancer
April 21, 2015
Dr. Bishoy Faltas on the Future of Bladder Cancer Therapy
April 17, 2015
Dr. Serena Wong Discusses Cognitive Dysfunction After Cancer
April 16, 2015
Oncology Nurse Michelle Gervino Discusses the Importance of Caregivers
April 15, 2015
Surgery Versus Radiation in Prostate Cancer
April 13, 2015
Advice for Patients with Newly Diagnosed Glioblastoma
April 13, 2015
How to Return to a Daily Routine After Melanoma
April 09, 2015
Megan Miller Shares Her Experience with Skin Cancer
April 08, 2015
Dr. Deanna Attai on Why Cancer Patients and Survivors Should Explore Social Media
April 02, 2015
Study Reveals Low Rate of Side Effects with Statins in Patients with Kidney Cancer
April 01, 2015
Sam Donaldson Discusses His Melanoma Diagnosis
March 30, 2015
Oncologist Hyman Muss on Physicians Helping Patients With Breast Cancer Make Decisions
March 26, 2015
Managing Side Effects of mTOR Inhibitors in Cancer
March 25, 2015
A Prescription for Active Surveillance of Prostate Cancer
March 23, 2015
Dr. Adam Asch Encourages Lymphoma Patients to Fully Understand Their Diagnosis
March 22, 2015
Improving Communication Between Cancer Patients and Physicians
March 20, 2015
The Importance Behind Screening for Lung Cancer
March 20, 2015
Former Astronaut Tom Henricks on the Importance of Trusting Your Oncologist
March 20, 2015
Smoking Cessation Encouraged for Patients with Cancer
March 18, 2015
Howard Hochster, MD, Explains Colorectal Cancer Screening Guidelines
March 16, 2015
Jacquelyn Lauria, RN, on Lifestyle Changes After Cancer
March 13, 2015
The Importance of Having a Relationship with Your Oncologist
March 11, 2015
Lifestyle Recommendations for Newly Diagnosed Pancreatic Cancer Patients
March 11, 2015
Dr. Stuart Goldberg Answers Common Questions From CML Patients
March 06, 2015
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
March 04, 2015
Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference
March 04, 2015
Genetic Testing for Women at High Risk for Breast and Ovarian Cancers
March 04, 2015
Surgical Updates from the 32nd Annual Miami Breast Cancer Conference
February 28, 2015
Medical Updates from the 32nd Annual Miami Breast Cancer Conference
February 28, 2015
Richard Joseph Discusses Treatment Outcomes for Metastatic Melanoma
February 19, 2015
Overcoming the Fear that Comes with a Diagnosis of Metastatic Melanoma
February 18, 2015
Molecular Profiling for Patients With Non-Small Cell Lung Cancer
February 13, 2015
Oncologist Mark Socinski on VeriStrat Testing for Patients With Non-Small Cell Lung Cancer
February 12, 2015
Thomas Stinchcombe Discusses Immunotherapy Breakthroughs for Lung Cancer
February 11, 2015
Genetic Counseling and Testing Offers Important Information for Breast Cancer Patients
February 10, 2015
Oncologist Beth Overmoyer on Inflammatory Breast Cancer
February 10, 2015
Anne Quinn Young, of the MMRF, Discusses Immunotherapies Being Studied in Multiple Myeloma
February 06, 2015
Michelle Gervino Discusses the Benefits of Communicating with Your Nurse
February 04, 2015
Myeloma Expert Brian Durie Discusses the ASPIRE Trial
February 02, 2015
Oncologist Suzanne L. Topalian Describes New Melanoma Treatments
January 30, 2015
Anees B. Chagpar Explains the Impact of Lifestyle Changes on Reducing Breast Cancer Risk
January 28, 2015
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
January 27, 2015
Jenna Forsythe Gives Advice to Patients Newly Diagnosed with Cancer
January 26, 2015
Oncologist Lewis Silverman on Revlimid for Patients with Myelodysplastic Syndrome
January 23, 2015
Oncology Nurse Linda Casey Offers Advice to Cancer Caregivers
January 23, 2015
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
January 22, 2015
Gastric Cancer Advocate Debbie Zelman Talks About Need for Education and Support
January 20, 2015
Breast Oncologist Beth Overmoyer Explains Results of Ovarian Suppression
January 19, 2015
Urologist Raoul Concepcion Explains Gleason Score and Gleason Grade
January 14, 2015
Charles Balch Discusses Project Innovation
January 12, 2015
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
December 12, 2014
Follow Up Study Data Draws Attention to Benefit, Side Effects of Adjuvant Chemotherapy in Breast Cancer
December 12, 2014
SABCS: Debu Tripathy Discusses PI3 Kinase Inhibitors in Breast Cancer
December 11, 2014
SABCS: Debu Tripathy Discusses Immunotherapy in Breast Cancer
December 11, 2014
Greenberger Explains Why Immunotherapy Will Be an Important Class of Therapies for Blood Cancers
December 10, 2014
MMRF's CoMMpass Study Highlights and Moves Research of Myeloma Forward
December 10, 2014
Oncologist Richard T. Silver on Receiving the MPN Hero Award
December 06, 2014
David Alexander on the MPN Heroes Program
December 06, 2014
Antje Hjerpe Discusses Her Passion for the MPN Community
December 05, 2014
Artist's Balancing Act Inspires New York's Hope Murals Project
November 13, 2014
Oncology on Canvas Winner's Cancer Experience Shapes Her Artwork
October 31, 2014
Oncology on Canvas and The Hope Murals Project Reaches New York City
October 31, 2014
How Will Breast Cancer Surgery and Treatment Improve Over the Next Five Years?
October 15, 2014
Patrick Borgen, MD, on the Future of Personalized Medicine in Breast Cancer Care
October 15, 2014
Latest Updates in Cancer Research Announced at European Oncology Congress
October 09, 2014
The Ongoing Mammography Debate: Does Routine Screening Matter?
October 01, 2014
Does Prophylactic Double Mastectomy Make a Difference?
October 01, 2014
Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer
October 01, 2014
ASCO: Early Studies Show Promise in Treating Metastatic Breast Cancer
June 05, 2014
ASCO: More Answers, and Questions, on Best Hormonal Therapy for Early-Stage Breast Cancer
June 04, 2014

EDUCATED PATIENT Lung Cancer Webinar: Midwest Region

CURE hosted its first webinar, focused on all the latest topics and trends for patients with lung cancer. 
BY CURE Staff
PUBLISHED May 22, 2020


Lung cancer is the most common form of cancer in the United States and is the deadliest. However, the lung cancer landscape is evolving to meet the demands of the disease and find new ways to detect, prevent and treat lung cancer.

On Thursday, June 4th, CURE® gathered top experts in the field of lung cancer for an informative lung cancer webinar focused on topics that were highly relevant to patients, caregivers and advocates, including current trends with lung cancer diagnoses, COVID-19 symptom overlap and minimizing risk, biomarker testing and more.

Panel faculty include:

Leora Horn MD, MSc
Associate Professor & Clinical Director, Thoracic Oncology Program at Vanderbilt University Medical Cancer.
 
Jyoti D. Patel, MD
Professor of Medicine at Northwestern University.
 
Allison Schaffer
LCSW Private Counseling Practice
Lung Cancer Research Foundation Patient Educational Programs Review Committee

Transcription:
DR. LEORA HORN:  Hello, everyone, and welcome today to the live broadcast Cure Education Patient Lung Cancer Webinar.  I am Dr. Leora Horn, an associate professor at Vanderbilt University Medical Center here in Nashville, Tennessee, and I'll be your moderator for this evenings' event.  We're pleased to bring you this webcast presented by Cure and sponsored by AstraZeneca and The Lung Cancer Research Foundation.  I have a couple of important announcements before we begin. 
First of all, this webcast is designed to be interactive and we encourage you to ask questions during the event.  You can submit questions by typing it in the Q&A box which can be found at the bottom of your screen.  If you have any technical problems viewing or hearing this presentation, please click on the question mark help widget in the doc at the bottom of your presentation window and we'll be taking questions and answering them throughout the hour. 
I am pleased to be joined today by Dr. Jyoti Patel, Professor of Medicine at Northwestern University in Chicago, Illinois.  The place that we normally go around this time of year to see ASCO.  And someone from my own backyard, Ali Schaffer, a licensed clinical social worker and member of the patient education program through the view committee at the Lung Cancer Research Foundation.  Thank you both for joining me today. 
So, there has been a lot going on in the world with COVID-19 and also, recently, at ASCO with the updates that we had on our lung cancer patients.  And maybe I'll start with you Jyoti.  And just thinking about ASCO and what we saw this past week, if you could pick one presentation, I think we'll get to a lot of the data.  What was the one thing that you were most excited about to see at ASCO this year?
DR. JYOTI PATEL:  So, certainly, leading up to ASCO, it's been a pretty exciting time.  We know there have been multiple sorts of press releases and drugs that were approved in May.  But really, I think the one is the single study that was so impactful to patients is the use of adjuvant osimertinib in the ADAURA study.  This is a complete paradigm change for our patients.  It really brings targeted therapy to the curative setting for a subset of patients. 
DR. HORN:  So, yeah.  So, I think I agree with you.  I was very excited about ADAURA.  And just to remind those people who are on the chat, it was a randomized phase III trial that was comparing osimertinib after chemotherapy to placebo in patients who had EGFR mutations.  And what the study showed us was that there was an improvement in disease-free survival for patients who got osimertinib.  A very significant improvement in disease-free survival.  And we're waiting to hear about the overall survival data.  And Ali, you do a lot of work with patient groups and patient advocates.  Do you think it's enough for an oncologist to go to their patients tomorrow and tell them we've got a drug that is going to prolong your disease or prolong the time until your disease comes back?  Or do you think that patients are going to say, wait, I’m not going to do this because it's meant to help increase the chance of cure and we don’t have that data yet?  What should we be telling our patients?  How should be thinking about this data?
MS. ALI SCHAFFER:  Yeah, what a great question and I think it's a collaborative conversation.  And so, the medical providers who bring their expertise of what they know and what has just been released through ASCO.  And the patient can bring their expertise of self and what's important to them in their own life to have a discussion.  To share information, ask questions.  So, at the end of any kind of conversation, a - - feel empowered with information to make what makes them feel like an informed choice instead of - -.  So, I think - - is the providers who help patients understand how this data applies to them and their particular individual medical - -, medical risk.  To give them support and - - them decisions.  Also, provide that there is a time-sensitivity of the - -.  That can be a really helpful factor as well. [audio issues]
Patients feel there is an urgency to make decisions when that's not always the case.  So, as a provider, you could improve that.  This is something for you to think about and you have the amount of time, if not urgent or this is something that you really need to consider and decide within that couple of days, for example.  But knowing the timeframe, you can provide a lot of important - - patients to make decisions and also, to follow up when they have additional questions. 
DR. HORN:  So, Jyoti, I have two interesting questions in the clinic on Monday and I’m curious to see how you're going to answer these questions.  So, one was from a patient who saw the ADAURA data, but she's about a year out from finishing adjuvant chemo.  And she asked me, "Do I need to go on this now?"  So, what would you tell her?
DR. PATEL:  So, this is really tough.  So, just to remind everyone.  So, the ADAURA study was looking at patients with resected lung tumors and they got up to three years of osimertinib and osimertinib is the TKI that we know that is approved in the frontline setting.  The study allowed for chemotherapy and we think that chemotherapy is the standard of care after surgery for patients with stage II and III disease and certain patients with stage 1b disease.  So, all of these patients were - -.  The primary endpoint of this study was looking at patients with stage II and III disease.  And remember that these patients are at a high risk of relapse.  So, I think lung cancer is always tough when we talk about it.  Yes, it was in an early stage.  To even with stage I disease, up to 30% of patients will, unfortunately, suffer a relapse and the stakes are pretty high. 
We've shown since the early 2000s that chemotherapy after surgery decreases that risk of relapse, but honestly, those gains are somewhat small when you sort of see new gains with recent trials.  But those gains include survival benefits anywhere from about 3% to about 12% or 13% in patients with more advanced-stage disease.  So, like stage III disease.  What we saw with osimertinib after three years was that we decreased the risk of recurrence so significantly.  So, for patients with 1b disease by something we call hazard ratio 0.5.  So, that means that - - recur for patients with stage III disease.  Where the likelihood of recurrence is almost 70%.  That reduction in risk was almost 90%.  So, really positive studies. 
And so, the trial was designed such that patients needed to start one of those drugs, I think, within 10 weeks of completion of surgery or after chemotherapy.  And so, certainly, that year window is out.  We know that the risk of recurrence is highest in the first two years, but it doesn't drop off completely.  There’s still a risk of recurrence over two to five years and then at five years, we think it's generally new cancer.  I think they are astoundingly positive studies.  I understand exactly what you were saying.  Like that's a tough question.  So, are they outside of the window of greatest risk?  And at this juncture, are we just adding osimertinib and adding toxicities?  And the toxicities are mild, but they're there every single day.  You're taking a pill that causes some fatigue and rash and diarrhea.  And so, where is that piece? 
We know that recurrent disease, though very treatable, can be devastating, right?  So, a disease in the brain, disease in the bone, any symptomatic disease can be really difficult.  And so, I think it’s a very weighted conversation.  Honestly, Leora, for someone with early-stage, so 1b.  Certainly, I think I would be less inclined to prescribe it.  But in someone with stage III disease where the risk of recurrence is so significant, it may be reasonable to consider.  Currently, it's not FDA approved, so, you can't get it, unfortunately, but I think it's something that's certainly emotionally compelling to me despite the lack of data there.
DR. HORN:  Yeah.  So, we had a long talk that it's not in that approved indication.  This patient was 2a and so, we kind of settled on 17 months post-surgery and you're 12 months post-chemo.  And I think at this time that we could do more harm than good.  And so, I said let's just kind of wait because we also don't know how it impacts the long term chance of cure.  And at this point, you're already halfway through where you would have been, potentially, on osimertinib. 
So, I guess the other tough question that I had and maybe Ali, I know that you're not a physician, but you do have great insight into what patients are thinking about.  I had a patient who was alk-positive, so not EGFR, would not have qualified for this trial.  Who is finishing adjuvant chemotherapy and we've talked about the ALCHEMIST trial for them.  And the ALCHEMIST trial is the big cooperative group for all that's comparing crizotinib to the standard of care for patients who are ALK-positive.  And he turned around and said, "Well, shouldn’t I get one of the better alk-inhibitors like that ADAURA study, and shouldn’t I just go on alectinib because that's what is FDA approved and is better than crizotinib?" 
So, as Jyoti mentioned before.  Before ASCO, we had selpercatinib approved for patients who are - - fusion-positive.  We've also had the approval capmatinib.  Finally, we've got something for patients who have the MET Exon skipping mutation in their tumors.  What do we do for all these other drivers?  Because we're going to have patients asking us those questions and where do we direct patients?  What should we be telling them?
MS. SCHAFFER:  Yeah.  So, that raises the point that chemotherapy or targeted therapy or immunotherapy is one part of a comprehensive care plan.  How do you help patients?  How do you help families have additional information and support and community?   What are the additional actions that people can take that might also support their care?  And so, helping them to see what else can you do in addition to some of these treatment regimens?  How else can you support yourself and take care of yourself and some of the additional methods?  Nutrition, rest, stress management, counseling, emotional well-being, connection to the community, peer support, fitness, movement, exercise, some of the additional therapies.  These are also part of the care plans and care regimens.  Patients benefit from having the consideration and the conversation and it means a lot when physicians bring in these topics as well.  So, patients and family members can understand the importance of these actions, in addition to some of the targeted therapies and how people are making choices. 
DR. HORN:  Yeah and I don't know about your, Jyoti, but I said to my patient.  I said, "I think this is even a bigger reason to go on ALCHEMIST, so we can answer these questions and figure out what we need to do for you after you have finished chemotherapy."  I hope this doesn't become a reason the patients don't do chemotherapy because we don't have enough data on substituting chemotherapy for targeted agents or immunotherapy.  We know that those trials are ongoing.  But hopefully, we're going to get that. 
So, other data that we saw at ASCO.  You sort of had that perfect segue, Ali, saying immunotherapy and chemotherapy and you know we can not talk about immunotherapy when we talk about lung cancer.  And we had some updates.  I feel like it wasn't as exciting this year at ASCO for immunotherapy this year, very much my bias.  But we had updates from KEYNOTE-189 which was the trial that looked at carboplatin and pemetrexed with pembrolizumab.  That got pembrolizumab approval.  We had some three-year updates from CheckMate 227 which came just as nivolumab and ipilimumab.  It got FDA approval as a first-line option in patients who are PDL-1 greater than 1%.  So, Jyoti, with your new patients in the clinic.  You now have a multitude of choices.  There's not just one choice.  When you looked at those trials and I don't know if you want to discuss and help me describe some of those trials to our audience.  What did you go with on Monday saying here's what's different and here's what's new what we need to talk about and offer you as a new standard of care?
DR. PATEL:  Sure.  So, the gates seem, in many ways, wide open and I’m trying to make my decisions less arduous.  So, going in ASCO, we had ideas about patients with targeted oral mutations that certainly go on targeted therapy.  Patients who are ineligible for those.  We sort of look at their PDL-1 status to relegate whether we do single-agent immunotherapy, chemotherapy with immunotherapy.  It was relatively straight forward unless someone had a real pushback or quality of life concerns about starting chemotherapy.  If someone's number was greater than 50%, they got single-agent pembrolizumab.  If it were less than 50%, you could get chemotherapy with pembrolizumab.  And there are also other combinations with the atezolizumab, but I think sort of most of us tend to do the drug that was approved first. 
So, in the month and days preceding ASCO, there were two approvals in the frontline setting that I think is really important.  And what was presented at ASCO was the updated anAlisis of CheckMate 227.  This is a trial that has been ongoing, and I think it’s gotten a fair bit of sort of discussion about how the trial has morphed over time.  Nevertheless, the regimen that was finally approved was nivolumab and ipilimumab in patients who had PDL expression greater than one.  We have seen other dices of this trial and we know that this can be a regimen that's quite active in patients with no expression of PDL and PDL-0.  But the FDA approval and the primary endpoint of the trial really focused on this population with some PDL expression.  So, that's what was approved. 
What we saw at ASCO, I think was really exciting.  It was the three-year updates on this regimen and a couple of things to me really stood out.  One was that patients who got ipi-nivo and had a good response at six months seemed to sort of plateau for the next three years.  So, that early response sort of indicated this prolonged benefit from these drugs.  So, I think that's really compelling.  There's a subset of patients that do very well for a long time with both CTLA and PD inhibition. 
The other piece I think that was really exciting about sort of these regimens.  Again, even if we don't look at that sort of landmark analysis at six months.  It was the proportion of patients.  About a third of patients on ipi-nivo, regardless of how they did, continued with disease control at three years.  So, certainly, without chemotherapy, we thought that was pretty exciting in the entire population greater than 1%.  I think right before ASCO, there was another approval of chemotherapy with ipi and nivo and Leora, maybe you want to talk about that.  Because I think that's what, probably, is most exciting to me.  To how to sort of fit this in the paradigm, but the one that's most perplexing as well.
DR. HORN:  Yeah.  So, that was the non-LA [phonetic] study which looked at chemotherapy with or without nivolumab and ipilimumab.  And it showed improved response rates, progression-free survival data compared to chemotherapy.  And I think we've had a lot of trials that have shown this.  What was interesting to me in that study is the toxicities were really not that high, but patients only had two cycles of chemotherapy with nivolumab and ipilimumab and then continued with the nivolumab and ipilimumab.  And so, part of the thought behind that study was could you also-- a lot of the trials that we look at, we see a lot of patients who get single-agent checkpoint inhibitors or even nivolumab and ipilimumab had this rapid progression. 
And so, we didn't see the question was could you flatten that curve a little bit in the first two cycles and then maintain the responses with nivolumab and ipilimumab.  Someone asked me the other day which combo I’m going to use, and I don't know that I’m going to jump to that, but the answer that I had from them is that we have so many drugs with such similar data.  And I said to them, "I'm going to use the one that's least expensive, but they're all the same price right now."   But I’m curious to think and get your opinion on this, Ali because I know this probably something very important to our patients.  It's important to society really.  It's the cost of care.  That’s where my Canadian training always comes back to me. 
But we've got so much data now showing fairly similar outcomes.  I actually would be more excited if the FDA had approved nivolumab and ipilimumab in the PDL-1, 0 patients because that would have given me a non-chemo regimen rather than getting another chemo regimen.  So, Ali, did you hear much buzz from folks about these regimens?  What are your thoughts about the cost of these different drugs?  Because they are fairly cost-prohibitive.  I'm just curious about what you thought of the data.
MS. SCHAFFER:  Yeah, it's challenging because we can't look at care without looking at cost of care.  And yet we never want that to be the driver of the decision making when we are balancing that against someone’s life or someone’s extended life expectancy.  So, it becomes a real stress point for patients and families wanting to have a quality of life, wanting to have a quantity of life and also, trying to make decisions when some of these treatments are incredibly cost-prohibitive. 
Cancer care is expensive and there are many organizations that are trying to support an offset, some of that funding.  But that becomes very real factors in decision making.  One of the challenges is for patients to be able to get upfront, true, and static costs of what some of the treatment decisions are going to be and they can't always get that information because there might be changes in cost or ancillary things that come up as they need more, maybe, supportive care as they're needing side effect management.  And so, even if they did have some of those static costs of treatment upfront, it doesn’t mean that's what's going to be the case over time. 
And so, again, it comes into conversations.  What do they have available?  What are they willing to do?  Talking with insurance providers, talking with their treatment providers.  But it's really a hard thing when it comes down to cost and is that going to be the thing that keeps somebody alive or extends someone's life.  Nobody wants to have to make that choice based on cost. 
So, that's not a simple answer and there's not a simple pathway forward except ask a lot of questions, decide personally what you're willing to do, and what is available to you.  And then work with your providing team to make the best choices that you can. 
DR. HORN:  Yeah and it's amazing to me to see how well our lung cancer patients are doing.  People are living for a long time and so, it's not like you can budget for a six-month illness and stage IV disease.  Because now, patients with stage IV disease.  I have some patients in a decade.  That's because I’ve only been practicing on my own for just a decade.  And it's just so good to see them and hear about their children and their grandchildren and their lives.  When people come and you're not talking about cancer therapy for the entire visit.  You know that things are going well.  But I’m hoping that what happens in lung cancer is what happened in hepatitis.  When we had so many disease drugs for the same indication.  We suddenly got drugs that were affordable. 
One of the questions that came through was what about immunotherapy for patients with k-ras mutations?  Did we see any new data this year?  Last year, we saw a really nice analysis from Dr. Skelidus [phonetic] who looked at patients who were getting chemotherapy with immunotherapy.  Maybe these patients had k-ras mutations, but maybe they also had LKB-1 or STK-11.  And his data showed us that those patients who had those co-mutations.  Maybe they didn't do as well with immunotherapy and we need to be thinking about other treatment options.  I don't remember seeing any great updates for immunotherapy with the k-ras mutations, but Jyoti, maybe you want to talk about some of the data that we saw with the new k-ras inhibitors that seem to be coming down the pipeline at ASCO this year.
DR. PATEL:  Sure.  So, certainly, we know that k-ras mutations are quite common and that there are a number of different subtypes.  The most common k-ras mutation that we see is G-12-C.  And so, there has been, I think, for the past year, multiple presentations about AMG-510, as well as some smaller ones about IM/RADI compound.  These are oral drugs that appear to have really good efficacy.  The numbers are small.  I think questions about the durability of response remain.  This year at ASCO, we saw AMG and other tumor types.  So, we saw some responses in small cell, as well as in colon cancer.  An idea that this is a legitimate pathway, but also, understanding that perhaps these drugs are less effective in colon cancer than in lung cancer.  And it may be because of downstream pathways.  So, certainly, I think there's a lot there to continue to learn about and we'll see what some of these registration trials look like.
There was some information about STK, and these are the numbers that we get.  On most of our mutation panels, we have a lot of mutations and we think that we may be able to understand the immune response.  I give STK as part of my panel at Northwestern and I think most commercial vendors give it as well.  Thus far, I have not used it as assigned therapy.  I've used it as part of a clinical trial.  There were a couple of studies suggesting that STK and other mutations may be more prognostic than predictive of response to certain drugs.  So, it may be that these similar mutations make the response to immunotherapy less effective, but I think it needs a lot of further study. 
So, at this juncture, if someone had an STK mutation, I wouldn't hold immunotherapy.  I don’t feel like I have enough information.  I think it would be - -.
DR. HORN:  Yeah.  I wouldn’t hold it, but I’m more likely to give it in combination with chemotherapy.  That's sort of been the way I’ve looked at those reports that we get on our patients. 
DR. PATEL:  I absolutely agree with that.
DR. HORN:  One of the other exciting presentations that I think I’d put up there in my top five, although, it wasn't in the lung session.  It was the antibody-drug conjugate in the DESTINY-1 trial.  And I know I’m going to butcher this name.  Trastuzumab or deruxtecan.  Or I’m sure we're going to come up with a nice short form for it.  So, we got excited a few years ago about DLL-3 and ADC with Rova-T.  That looked good in phase I, but it seemed to have these toxicity signals and fell apart.  But the DESTINY-1 trial looked at this agent that is currently approved in breast cancer patients.  So, I feel like we've got more safety data and it looked in patients with HER-2 mutations.  And we saw a response rate of over 60%.  We saw a PFS of around 14 months.  Is this something you're excited about that you think that we're going to see more of?  This was in a combined GI and lung cancer patient population, so small numbers.  It was the second line.  It wasn't first.  But have we finally got a targeted agent for HER-2 positive patients, do you think?
DR. PATEL:  HER-2 mutations have been really tough.  Often, they are lumped in these clinical trials with EGFR Exon-20.  What we've seen is most of the TKIs that have been tested are minimally effective, come with toxicities.  It's a tough nut to crack in many ways.  So, certainly, I think we are really excited about this ADC. 
There was pneumonitis in the study.  A little bit more than we usually see, about 5%.  So, I think that needs to be sorted out.  The numbers were small, but certainly, how great to have a drug for this distinct subset and I’m anxious to watch it move forward in larger trials. 
DR. HORN:  And I’m quite curious to see, for those patients who got pneumonitis, had they got immunotherapy before.  And so, is it a combo or the ADCs with the chemo?  Ali, should be trying to advocate to get this drug for outpatient when it's not FDA approved, or should we tell our patients to hold your horses?  I actually had an HER-2 positive patient in the clinic on Monday who's on a clinical trial and I kind of mentioned the ASCO data because I spent the whole weekend watching Zoom with my kids, ASCO on Zoom.  And so, what do you think we should do for our patients with this drug, or do we still need to wait for more data?  Oh, Ali, I think you’re on mute.
MS. SCHAFFER:  I am, thank you.  Any time there's an opportunity to advocate on behalf of treatment regimens.  That there is data to prove it or sufficient things to say we need more.  Absolutely.  Taking that approach of advocacy with all of the different avenues that you have.  I think it brings the point that patients and families are hearing some of this information.  They're getting excited and they're getting really hopeful.  And that's a huge thing.  It's there's hope associated with some of these new regimens.  And then it's also taking away that hope and feeling pretty heartbreaking when they hear, "Oh, but we can't get it," right. 
So, I think it is a really important thing to be aware when you offer a potential treatment regimen that's not actually available.  How that might be impacting the emotional wellbeing and the hope of a patient and the family of what might be available.  Because what they're invested in is their life.  They want to live, right.  Patients and families are involved with the treatment and doing these things because they want to live.  And so, hearing that there's a treatment that's not available to them that might actually serve them is a really hard place to sit for a patient.  So, anything that you can do as physicians to advocate and to create access to this treatment is incredibly important and I would say yes every time. 
DR. HORN:  Yeah.  I think another reason to keep encouraging our patients to go on clinical trials.  And I feel like in the lung cancer community we're very lucky.  It's a collaborative group and if we hear about something that's better than what we have down the road or across state lines.  If you're allowed to cross the state lines right now, then I think it's a reason to send those patients.  So, Jyoti, we have a question from a patient.  If someone is exhausted their TKI options and their PDL-1 score is zero, do any of the new approvals apply?  So, should that patient get nivo and epi or should they get chemotherapy with nivo and epi?  What can we offer?  Because we've heard a lot.  We've seen data out of some different institutions showing that patients who have driver mutations maybe don't derive as much benefit from treatment with checkpoint inhibitors.  What would you tell this patient?  What would you recommend?
DR. PATEL:  Sure, it's tough because we really don't have very much data.  So, we know it's single-agent PD-1 inhibitors or PDL-1 inhibitors, the response rate in patients with the driver mutation.  And not all driver mutations.  Let me sort of step back a little bit and say EGFR, all, and ras-1.  We have pretty good data about it.  But their response to single-agent immunotherapy is less exciting.  A couple of years ago, Matt Hellmann presented data with epi and nivo in patients who were sort of post-TKI and there was certainly some feeling that some patients with EGFR mutations who had progressed were having responses.  Honestly, I think as that data has matured, many of us have felt that maybe that was just early numbers and hasn’t matured as nicely. 
It's tough, also, because the FDA approval for carboplatin, pemetrexed, and pembrolizumab excluded these patients and we know that carboplatin and pemetrexed are sort of a backbone for patients after the failure of TKIs in patients with driver mutations.  So, we've kind of been left with the only real data we have which is a combination of carboplatin, paclitaxel, bevacizumab, and atezolizumab in these patients.  And certainly, we know that the addition of anti-VEGF with bevacizumab plus atezolizumab improves outcomes in this subset of patients.  The improvement is, I think, a little bit more modest and the numbers continue to be small, but this is an area of active investigation. 
So, there are a couple of trials right now that are looking at these particular populations to better define what response would look like and whether or not we could sort of switch chemotherapy backbones.  So, I’m optimistic that we'll have more agents.  Currently, what do I do off of a trial for many patients?  For a patient with an EGFR mutation, often I'll actually continue the osimertinib and add chemotherapy, sometimes, with or without bevacizumab.  It depends a lot on what burden of disease they have.  Generally, I think our paradigm has shifted a lot in the past several years.  If a patient develops resistance, we try to do another biopsy to understand the mechanism of acquired resistance and whether we can use two targeted therapies to overcome that resistance or whether or not systematic chemotherapy is appropriate, and then we sort of add on to it.  Sort of the paradigm I have is that really we want to think about the longest time that we can have disease control because the science is evolving so rapidly.  The cadre of clinical trials and our early discovery of understanding mechanisms of resistance is changing dramatically in years.
So, even if a patient can go on chemotherapy for a year or so on a regimen that's effective and has low toxicity.  And yes, it's a drag getting infusion therapy after you've been on oral chemotherapy, but if we can get even a year.  I'm optimistic that the science evolves in that time and certainly, we're seeing that more and more with the number of agents that we're bringing from VEG to bedside.
DR. HORN:  Yeah, definitely and you know what?  I always worry about when I give a patient with a mutation, a checkpoint inhibitor.  When I want to give them another TKI because there's something newer or better, they might add more toxicity to that TKI. 
So, Ali, as Jyoti mentioned, we're looking for a longer time with disease control because lung cancer patients have such a better prognosis.  That's always the first thing I tell my patients.  So, as someone who's working with people who are impacted with cancer, who are specifically supporting their emotional wellbeing, what do you want people to know?  What's important for people who are listening to us today to think about for these patients?
MS. SCHAFFER:  Yeah.  So, hope is one of the things that first come to mind.  How important and how personal hope is.  That hope means something different to every person.  And so, for all of the healthcare providers, as well as the families and patients living with and impacted by lung cancer to really be willing to bring hope into the conversation and into the care plan and into their daily lives as a way of coping with a cancer diagnosis. 
Let's be clear, cancer diagnosis, at it's basic, is a life disruption and it has various implications and magnitude for each individual.  And there is likely going to be an emotional impact.  It doesn’t mean that someone can't develop coping mechanisms and skills to deal with and respond to the impact of a cancer diagnosis.  But I think as someone who is a clinical social worker, again, working with people around emotions.  Every day I’m helping people learn how to feel their feelings around a diagnosis, how to create their own roadmap for what it means to stay engaged in care and to develop coping mechanisms to help them tolerate treatment, help them stay engaged in day to day life, and having a meaningful quality of life and meaningful personal connections. 
So, another thing I’d like to really remind people of is the power of community.  So, tonight we're all coming together to share information, to ask questions, and I want to remind everybody that there is a lot of incredible online support and personal support about the lung cancer community.  As a representative of the medical advisory review board with The Lung Cancer Research Foundation, I know they're one of the organizations that are doing a lot to fund research, to provide access to information to patients and families.  They have peer support, peer mentors.  So, both caregivers and patients.  And in addition to The Lung Cancer Research Foundation, Cure Magazine is a huge wealth of information and community.  So, there's so much out there and available and I want to remind people to use the connection of community and use the connection to information for their own wellbeing and for their own care of treatment decisions and quality of life.
It's so important that we look at the broader scope of care to include all of these aspects and I want patients and healthcare providers to leave feeling empowered.  That they have the ability to participate to make change in individual lives and that it really does matter.
DR. HORN:  Absolutely and-- sorry, go ahead, Jyoti.
DR. PATEL:  I was going to say it's so important for us to realize.  Like these past months for all of us have been so disrupted.  Sort of the communities that we surround ourselves with, all of our bolsters, and our emotional wellbeing.  Sort of even that physical sense of being close with people has been so disrupted and this can be a lonely disease and I think during this pandemic, it's even lonelier.  One of the most important studies I actually want to highlight.  Leora got to present sort of an international collaboration that she's leading, looking at the effect of Coronavirus in patients with thoracic cancers.  And that kicked off all of ASCO, right.  I mean it was one of the most important pieces.  The pandemic disrupted not only our lives but also, this great meeting.  So, Leora, do you want to talk a little bit about that?
DR. HORN:  Sure, and I can probably answer one of the questions that came up about our lung cancer patients before COVID.  So, when the pandemic started, we didn't know how long this was going to go on for.  And so, we were sitting here in the U.S. waiting.  I feel like we're sitting in Nashville a little bit, still waiting to see what happens.  But Marina Garassino, who is a lovely medical oncologist in Milan, sent an email out to 50 of her friends which I think goes to show the collaborative environment of the lung cancer community because there's not a lot of groups that could do this the way it happened.  And she said, "That what's happening is terrible for our patients.  Not only am I worried about how they are doing, but I’m worried about delaying the care and we need to collect data." 
So, we were here in Nashville and I said, "Well, clinics are half-closed, and I can't get people to come in and we can do this.  We can collect the data."  And I hope it's a lesson to companies for future clinical trials because within two days, we had established a case report form and within a week of us deciding to do it, we had IRB approval at our university and Italy actually had IRB approval for a whole country.  And within about six weeks, we had collected data on 400 consecutive patients who were diagnosed with COVID and lung cancer.  And now, I don't want people to hear the data and be-- I think there's a concern, but I don't want it to be the wrong sort of concern.  And what we found is in patients with lung cancer, who developed COVID-19, the mortality was much higher than what we expected and higher than we've seen in other tumor types.  CCC-19 is another collaboration that's ongoing across The U.S.   They had data on about 100 patients presented at ASCO, about 100 who had lung cancer.  And they had about an 18% mortality and we had a 35% mortality in our patients.
We're looking at what were the risk factors associated with mortality?  The average patient was over 60 years old that was enrolled in a database.  The majority of patients which was really surprising to me either had not been treated.  So, they were getting diagnosed with lung cancer at the same time as they got COVID.  Or they were on their first-line therapy which meant that their oncologist thought that there was a good reason to be on treatment and that there was hope and options for those patients.  So, it's not like these were patients who were sicker from their lung cancer and later line therapy.
We found that patients who were older, over 65, who were maybe not as quite as fit.  Who were on higher doses of steroids and who had either chemotherapy by itself or chemotherapy with immunotherapy.  They were at higher risk of dying from COVID. 
Now, I think there are two important messages that came out of this.  One is that we need to be concerned about our lung cancer patients, but I think, importantly, we need to realize this initial group of data was at the height of the pandemic in certain cities.  Definitely in Italy, definitely in France and Spain where some of this original data came from, as well as some sites in the U.S. such as New York. 
We're now up to over 600 patients and our goal is to get over 1000 to better understand some of this and we're starting to see in screens some of the asymptomatic patients at our centers.  What it said to me is we must stop giving our patients the first best therapy.  If we think that chemotherapy is going to be beneficial for our patients.  If we think chemotherapy and immunotherapy is the right treatment to do, don't forgo the chemotherapy and just give the immunotherapy.  Because sometimes, we've got one chance at really controlling the disease, but we need to minimize the patient's interaction with the healthcare system.  So, don't bring patients in for weekly labs.  They don't need it.  Let them come in once, get their treatment, go home, follow up on the phone, follow up on telehealth, follow up however your different institution is able to do it. 
But I think that we still need to offer our patients the best level of care.  What we've seen in The Netherlands which is scary, and I think we're going to see the same thing here.  It's that the number of patients going in for screening has decreased and that is a big concern.  Because last year, we had improvements in cancer mortality, specifically, due to lung cancer.  Are we going to see worsening cancer mortality when we get lung cancer statistics in the next two or three years as patients delay care?  And I do worry about that, but I think what - - did tell us is that our patients are at risk.  When you get chemotherapy, you should continue social distancing even if your city or country is opening up.  You should continue to be careful.  You do need to be that little bit more rigid in how you're living your life right now.  Because to beat cancer so to speak or get that cancer under control.  To die from this virus just seems so not fair for our patient population. 
Ali, what are you telling patients who are worried about going to their doctor?  And Jyoti, Chicago is not like Nashville.  We have no public transit.  You probably have a lot of patients taking cabs and public transit to get to Northwestern.  What are you guys telling patients out there from the - - data?
DR. PATEL:  So, certainly, our experience at Northwestern has been that we've actually seen very few patients with lung cancer and COVID in Chicago.  I think we really did a great job of flattening the curve.  Although we had a big spike, it was much less than projected and I think social distancing has worked.  I'll say over and over many of us in healthcare or parts of clinical trials.  I'm getting my serology tested often.  I'm high risk of going to the hospital.  I've volunteered in the inpatient service.  I think in the hospital and at points of healthcare, I actually feel we're quite safe because there's a code of conduct.  Everyone is screened for symptoms.  There's hygiene.  People wear masks.  And so, my message to patients is that if you need care, you need to come to the hospital because it's actually a pretty safe place. 
The other piece is sort of the silver lining of all of this.  I think we've gotten much more creative in how we deliver care.  It's much more patient-focused.  Patients come to the hospital at points of need.  I'm not doing extraneous visits and blood tests if patients don't need something from me or don't need an intervention.  Incongruent with this was also that we had some changes in the FDA label for the dosing of certain immunotherapies.  So, suddenly that could be atezolizumab and durvalumab.  In small cell longer cancer, it can be given every four weeks instead of every three weeks.  So, certainly, I think there's an effort to streamline care.  The FDA has issued a bunch of guidance about clinical trials.  We may be able to get blood draws and imaging at such sites off of the study site. 
So, I think there are a lot of things that will come from this that are much more patient-focused and will make trials easier to do in the long run.  But I think our immediate crisis is how do we keep people safe?  How do we assure people if they have symptoms, they need to come to the hospital and engage with medical care?  Because I actually think right now, most of the hospitals are pretty safe.
DR. HORN:  Are you swabbing?  We're swabbing patients before they start any therapy.  Are you doing similar things at Northwestern right now?
DR. PATEL:  We are.  So, patients are tested before procedures and at the start of therapy.
DR. HORN:  Ali, what are you hearing from patients?  What are the big questions?  How can healthcare providers support the patents?  How can the patient's families support them during this time?
MS. SCHAFFER:  So, there's a lot of uncertainty and uncertainly equals a lot of fear.  And so, some of the ways that I’m recommending.  What are the ways to reduce that fear?  And one of those things is get informed, get accurate up to date reliable information.  And then do the due diligence to check it out with your healthcare providers, right.  That's what you are here for.  It's to help patients to understand their risk, understand care protocols, understand the potential impact when some of these care protocols might change, right.  Because even when a patient is used to having a certain dosage or a certain timeframe of the treatment regimen, that becomes security, right.  And then when you switch that, that can inadvertently increase fear into stress.  And so, it's really important for patients to ask how might this change either my quality of life or my survival?  Or what is going to change?
And so, conversations and communication around the information.  Whether you're reading studies online, whether you're hearing things.  Because the cancer community is so connected, so patients are also hearing information from each other about what's happening where they live.  And as the two of you who are working in reputable institutions in different states, you're even checking out what are you guys doing?  Are you swabbing or are you not swabbing?  So, I think that even raises the point that patients might be hearing different things based on where other people are sitting in the world and it's still critical to bring it back to their healthcare providers.  To check it out as it relates to their institutions, their care teams, and their personal history.  That will help reduce some confusion and ideally, also reduce the fear associated with the uncertainty and the unknowns. 
Because what I’m hearing in this conversation today is how much the two of you are tapped into up to date information.  And so, I send all the people I’m working with to talk to your healthcare team if you have questions, whether you're in active care or not, follow back up with the people that are going to specifically answer it as it relates to you. 
DR. HORN:  Definitely and I think I’m always looking out for those updates.  So, Jyoti here's a question that came through.  For a patient who is on keytruda or pembrolizumab and they progressed, should they avoid chemotherapy?  Clinical trials are sparse right now.  Slowly, a lot of companies shut down their trials.  They are slowly opening them up.  What second-line treatment would you offer them and is chemotherapy a bad idea and they should stay with pembrolizumab?
DR. PATEL:  So, certainly, if the pembrolizumab is no longer working or the atezolizumab is no longer working, then I would advocate for trying something else.  And although chemotherapy for someone who's been on an oral agent, immunotherapy is really daunting.  It's quite effective and in many patients who have a good quality of life, minimal fatigue, minimal toxicity from chemotherapy.  And it may be as sort of a bridge to the next treatments.  Often, clinical trials will recommend immunotherapy, as well as a platinum treatment prior to enrollment on a clinical trial. 
Although medical research has stalled, large lung cancer trials have continued because often, being on a clinical trial is the best available option or the best therapy.  So, I think those will be prioritized at most institutions to open up.  But certainly, I think chemotherapy can be effective.  There is a large effort now called the INSIGNIA trial in which patients with some PDL expression either get pembrolizumab and then switch to adding chemotherapy to the pembrolizumab if it doesn't work or completely switching onto chemotherapy alone and forgoing further pembrolizumab.  So, certainly, I think we'll have clarity around these in the next years, but definitely a work in progress.
Understand, also, that we have, I think, a couple of years ago talked a lot about pseudo-progression and the patient who was having evidence of cancer progressing may actually be benefitting and to just be patient.  I think putting someone onto something because it's comfortable and not working is probably not serving anyone that well and probably the number of patients who have pseudoprogression is really benefitting is quite small.  So, I would say take the plunge and consider it and more clinical trials to follow.
DR. HORN:  Definitely and we had a similar question from someone who said they are responding to pembrolizumab.  What comes next?  And they have 100% PDL-1 expression.  I'm hoping that you don't need the, "What comes next," but I think Jyoti covered that.  We don't have a lot of time, but the last thing that I wanted to cover because it's something near and dear to my heart to where I live is small cell.  And we had some updates at ASCO for patients who had small cell lung cancer.  We had updates from the CASPIAN study.  This was a trial that looked at chemotherapy with or without durvalumab for patients with small-cell lung cancer.  There was an update for patients who had brain metastases that were untreated, and the trial showed us that durvalumab did have a benefit in those patients even if they had untreated brain metastases.  And we also had updated data from KEYNOTE-604 which was a randomized phase III trial that looked at chemotherapy with or without pembrolizumab which showed an improvement in progression-free survival, but there was not an improvement in overall survival. 
When you looked at ASCO, did any of this sort of change you're doing for your patients with small cell lung cancer?  If they present and have brain metastases, it's a tough one.  Are you recommending not to radiate?  Let's do chemo and see what happens.  How are you approaching those patients after ASCO, Jyoti?
DR. PATEL:  So, certainly, I think we finally changed paradigms with patients with small cell lung cancer over the past year or so.  So, with the durva data, I’ve been enrolling patients with clinical trials or treating patients with brain metastases with durva front.  I think the data is now a little bit more grounded and I feel quite comfortable treating those patients.  I think sort of the takeaways for me in small cell was that although the pembrolizumab trial was negative, the curves looked a lot like what we've seen with other regimens.  And so, I think IO and chemotherapy are effective for this group of patients.  I think it was probably a statistical issue or maybe a little bit of bad luck that the trial wasn't positive in OS. 
The other piece was that in CASPIAN - - in combination with the durvalumab.  It was a negative trial.  And in fact, I wonder if we actually hurt some patients with the addition of the fourth drug.  That's tough because we know - - inhibition with PD inhibition - - certainly, a group of patients that have long term survival.  And so, sort of figuring out when these drugs should be given, I think, still remains to be seen.
DR. HORN:  Yeah.  So, that was sort of a question that came up in the clinic when I was talking to my research nurses.  Because the ADRIATIC trial is open.  And what the ADRIATIC trial is, is a trial that is giving patients chemoradiation for small cell.  And once treatment is finishing, they're either being randomized to receive placebo, durvalumab, or durvalumab and tremelimumab.  And what we're hoping to see from this trial is the same benefit that we saw in non-small cell lung cancer.  That really led to the approval of immunotherapy for a year after treatment. 
Ali, do you think patients will have a reservation about getting durvalumab and tremelimumab now seeing that the CASPIAN study was negative?  Or do we say, well, that was with chemo, so we still need to look at this question because we don't have the answers?  Or are people talking about the small cell data?  Have you heard any concern in the cancer community?
MS. SCHAFFER:  People are talking about it because, of course, there are questions.  As you pointed out, there's not a clear answer.  There are still questions.  And so, again, it comes to talking.  I feel like I keep saying this, but it's really the most important thing.  It's to be in close communication with your healthcare teams.  To be making decisions based on your personal history, your personal risk factors, and your personal responses.  What's the best choice or what's the choice that feels most aligned for where you're at and what you're trying to accomplish and what the goals of care are.  So, there's always going to be questioning when there's no one way.  And through conversation and communication and close monitoring, I think those are the best ways to create the path forward.
DR. HORN:  Absolutely and Jyoti, I think we got time for one more question.  So, speaking of the PACIFIC data and looking at the osimertinib data for patients who got chemo and traditional therapy, should we be thinking about osimertinib for our patients who got chemoradiation therapy because they're such high risk?  There is a trial that is ongoing.  It's amazing to me how quickly immunotherapy trials close and open.  And for a while, I feel like there was TKI.  Just fatigue or less excitement.  And suddenly, we’re excited about TKIs again.  I'm excited about anything with lung cancer really that moves that curve forward.  And so, what do I do with my patients?  Do I say, well, we don't know, so let's keep up with the durvalumab?  Or should I talk to my patients about this again?  As Ali mentioned, it's not an FDA approved indication.  We don't have the data yet.
DR. PATEL:  So, certainly, in PACIFIC, the number of patients with the EGFR mutations was quite small.  We didn't know it for a huge proportion of patients.  It looks to be a trend, but it's a really wide confidence interval.  I guess mechanistically, to me, it makes more sense than probably a TKI should be appropriate there, but we don't have the data.  And in fact, when we looked at a TKI after chemoradiation in unselected patients, we actually hurt those patients in an older - - study.  And so, my sense is that the jury is still out.  Perhaps, I’m less willing or my threshold to stop durvalumab in these patients might be a little bit higher, so you develop a little bit of pneumonitis and I'll probably hold off.  But Leora, what are you doing?
DR. HORN:  Yeah.  I mean I’m seeing the same thing.  We don't have the data.  We don't know what to do.  I know that certain people are jumping on that, but I think we need to wait because we don't want to harm our patients and osimertinib can cause pneumonitis.  And so, starting that immediately after could put our patients just as much at risk. 
In the last few minutes or seconds, Ali, what are you most excited or most looking forward to for our patients coming up for the rest of 2020 besides a vaccine?
MS. SCHAFFER:  Yeah.  I think it's really the breadth and the width of treatment options that are available.  There's so much possible and that equals longer life, a better quality of life, and all of those things are really exciting.  That the lung cancer community continues to have possible options and that's really exciting.  That people are putting a lot of investment, a lot of money, a lot of time, and research into the lung cancer community.  Because it's an important population of people that deserve this kind of attention and these treatment options.  So, I’m excited about all the possibilities.
DR. HORN:  Jyoti, how about you?
DR. PATEL:  So, I think there's been a sea change in the past few years and it's high time, right.  I mean we've put in.  Sort if we work on the foundational science, patients have volunteered to be in clinical trials and to work with us.  But now, we're talking about really understanding what regimen to treat or the best data we'll have for regimens to treat patients with stage IV lung cancer.  It won't be real for five years, right.  We're seeing all of these immunotherapies, immuno-chemotherapy regimens, and we have data now at three years.  Now, it really depends on what that tail of the curve looks like. 
So, bringing better therapies, and really thinking about a longer patient journey, multiple options, holding off on toxicity, and keeping patients well as the science evolves.  That's what gets me excited with a really great group of collaborators and I think that's been sort of the story of 2020.  It's how people have pulled together during these tough times - -.
DR. HORN:  Absolutely and I hope those people listening out there come back to the clinic.  We're here to take care of you.  We want you to be safe and we don't want you to neglect your cancer care because you have good options.  And if you know people who qualify for screening, make them go get that CT scan because screening CTs can save lives. 
So, I want to thank our panelists and the audience for attending and participating in today's events.  I want to thank Cure and our sponsors, AstraZeneca and The Lung Cancer Research Foundation for making today's educational session webcast possible.  And I hope to see you all next time.  Have a good night.
DR. PATEL:  Thank you so much.
MS. SCHAFFER:  Thank you. 
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In